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ABSTRACT 
 
INNATE IMMUNE CELL REGULATION OF METABOLIC HOMEOSTASIS 
Jonathan R. Brestoff 
David Artis 
Obesity is an increasingly prevalent disease regulated by genetic and 
environmental factors.  Emerging studies indicate that immune cells, including 
monocytes, granulocytes and lymphocytes, regulate metabolic homeostasis and 
are dysregulated in obesity.  Group 2 innate lymphoid cells (ILC2s) can regulate 
adaptive immunity and eosinophil and alternatively-activated macrophage 
responses, and were recently identified in murine white adipose tissue (WAT) 
where they may act to limit the development of obesity.  However, ILC2s have 
not been identified in human adipose tissue, and the mechanisms by which 
ILC2s regulate metabolic homeostasis remain unknown.  Here, we identify ILC2s 
in human WAT and demonstrate that decreased ILC2 responses in WAT are a 
conserved characteristic of obesity in humans and mice.  Interleukin (IL)-33 was 
found to be critical for the maintenance of ILC2s in WAT and in limiting adiposity 
in mice by increasing caloric expenditure.  This was associated with recruitment 
of uncoupling protein 1 (UCP1)+ beige adipocytes in WAT, a process known as 
beiging or browning that regulates caloric expenditure.  IL-33-induced beiging 
was dependent on ILC2s, and IL-33 treatment or transfer of IL-33-elicited ILC2s 
was sufficient to drive beiging independently of the adaptive immune system, 
eosinophils or IL-4 receptor signaling.  We found that ILC2s produce methionine-
enkephalin peptides that can act directly on adipocytes to upregulate Ucp1 
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expression in vitro and that promote beiging in vivo.  Collectively, these studies 
indicate that in addition to responding to infection or tissue damage, ILC2s can 
regulate adipose function and metabolic homeostasis in part via production of 
enkephalin peptides that elicit beiging. 
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Chapter 1:  Immune cell regulation of metabolic 
homeostasis 
 
 
 
1.1  Obesity is a global public health problem regulated by genetic 
and environmental factors 
Obesity is in an increasingly prevalent metabolic disease characterized by 
excess accumulation of adipose tissue.  Obesity increases the risk of developing 
a wide variety of diseases including type 2 diabetes, cardiovascular diseases and 
multiple forms of cancer, and has been strongly associated with increased 
mortality(Collaboration, 2009; Flegal et al., 2013; Oliveros and Villamor, 2008; Pi-
Sunyer, 1999; Pontiroli and Morabito, 2011; Reilly and Kelly, 2011; Rodriguez et 
al., 2001).  In the past few decades, the prevalence of obesity has risen 
dramatically in both developed and developing nations across all continents 
(Kelly et al., 2008; Ng et al., 2014), and this has been associated with high 
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healthcare expenditures (Withrow and Alter, 2011).  For example, in the United 
States, where the prevalence of obesity among adults was 36% in 2010 (Flegal 
et al., 2012; Ogden et al., 2012, 2014), obesity accounts for approximately $190 
billion annually or 20% of total national health care expenditures (Cawley and 
Meyerhoefer, 2012; Finkelstein et al., 2009).  Therefore, obesity is a critical 
problem with major health and economic consequences.  Increasing our 
understanding of the pathways involved in the development of obesity will be 
critical for the development of new intervention strategies to prevent or treat this 
disease and its associated comorbidities.   
 
Genetic and environmental factors are important for the development of obesity 
and associated diseases (Bouchard, 2008; Brestoff and Artis, 2013; McCarthy, 
2010; Walley et al., 2009). In addition, emerging studies have implicated various 
cell types in the immune system as critical regulators of metabolic homeostasis 
(Jin et al., 2013; Lumeng and Saltiel, 2011; Odegaard and Chawla, 2011, 2013b; 
Osborn and Olefsky, 2012).  In white adipose tissue (WAT), which regulates 
metabolism at distant tissues such as the brain, liver and muscle, there is a 
diverse set of immune cells at steady state (Exley et al., 2014; Ibrahim, 2010; 
McNelis and Olefsky, 2014; Mraz and Haluzik, 2014).  This network of immune 
cells appears to be poised to recognize, integrate and respond to environmental 
signals including bacterial products, endogenous lipid species and hormones in 
order to coordinate metabolism (Odegaard and Chawla, 2013a).  Changes in 
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immune cell composition and function in WAT have been closely associated with 
obesity and the regulation of metabolic homeostasis, and disruption of this 
network of immune cells can have either detrimental or beneficial effects on 
mammalian health (Exley et al., 2014; Lumeng and Saltiel, 2011; Mraz and 
Haluzik, 2014; Odegaard and Chawla, 2013b; Osborn and Olefsky, 2012).  This 
implies that dissecting the complex interactions between immune and metabolic 
systems will be important for understanding the biology underlying obesity and 
have implications for understanding how current and future therapeutics might 
influence metabolism. 
 
The purpose of this Chapter is to describe our current understanding of how 
immune cells in white adipose tissue regulate metabolism.  First, we will 
summarize recent advances in the roles of white, beige and brown adipose 
tissues in the regulation of weight gain.  Second, we will describe the immune 
cell composition of adipose tissue at steady state and discuss how these immune 
cell pathways interact and contribute to the maintenance of metabolic 
homeostasis. Third, we will characterize immunologic changes that occur in 
adipose in the setting of obesity and discuss how these changes contribute to 
metabolic dysfunction. Finally, we will discuss potential therapeutic implications 
of targeting the immune system to treat obesity and its associated diseases. 
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1.2  Roles of adipose tissues in the regulation of obesity  
Mammals possess multiple types of adipose tissues including white, brown and 
beige adipose. These tissues are found in distinct anatomic locations and are 
comprised of different adipocyte cell types – white, beige and/or brown – that 
have unique developmental and functional properties that are critical for host 
metabolism (Fig. 1) (Bartelt and Heeren, 2014; Cannon and Nedergaard, 2004; 
Harms and Seale, 2013; Ibrahim, 2010; Peirce et al., 2014; Pfeifer and 
Hoffmann, 2014; Wu et al., 2013).  This section describes white, brown and 
beige adipocyte cell types and summarizes their roles in regulating weight gain. 
 
1.2.1  White adipocytes 
White adipose tissue (WAT) is distributed in subcutaneous depots and in 
association with organs, where it has important roles in insulation and physical 
protection of the viscera, and is comprised predominantly of white adipocytes 
(Peirce et al., 2014; Pfeifer and Hoffmann, 2014).  These specialized cell types 
arise from a Myf5− pre-adipocyte lineage and store large amounts of triglycerides 
in a single large lipid droplet (Pfeifer and Hoffmann, 2014; Sanchez-Gurmaches 
and Guertin, 2014).  In addition to their ability to store triglycerides, white 
adipocytes respond to hormonal signals to induce lipolysis and release free fatty 
acids (FFA) into the circulation for oxidation or storage by other cell types (Arner 
et al., 2011; Bartness et al., 2010).  Therefore, white adipocytes are critical for 
regulating both fat storage and release.  Beyond this function, white adipocytes 
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produce various adipocyte-specific hormones (also known as adipokines) such 
as leptin, resistin, retinol binding protein 4 (RBP4) and adiponectin among other 
adipokines that regulate metabolic homeostasis by acting on distant organs such 
as the brain, kidney, liver and skeletal muscle (Allison and Myers, 2014; 
Kadowaki et al., 2006; Kershaw and Flier, 2004; Kotnik et al., 2011; Lazar, 2007; 
Ouchi et al., 2011). 
 
In the context of obesity, mature white adipocytes become hypertrophic through 
accumulation of triglycerides (Kubota et al., 1999), and adipocytes proliferate to 
increase adipocyte numbers in WAT (Foster and Bartness, 2006; Hausman et 
al., 2001; Spalding et al., 2008).  As WAT expands, adipocytes increase 
production of leptin to suppress food intake and therefore limit the rate of 
triglyceride accumulation and adipocyte expansion (Allison and Myers, 2014).  
Leptin also has pro-inflammatory effects by eliciting type 1 effector cytokine 
production by immune cells (Attie and Scherer, 2009; Gregor and Hotamisligil, 
2011; Mraz and Haluzik, 2014; Ouchi et al., 2011).  In addition to leptin, RBP4 
and resistin production by white adipocytes are increased in obesity, and both of 
these factors promote insulin resistance in mice (Kotnik et al., 2011; Lazar, 2007; 
Moraes-Vieira et al., 2014; Norseen et al., 2012; Steppan et al., 2001; Yang et 
al., 2005).  Upregulation of RBP4 expression has been linked to inappropriate 
sensing of low glucose levels by adipocytes (Yang et al., 2005), whereas resistin 
levels are regulated by insulin and TNF-α among other factors (Lazar, 2007; 
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Song et al., 2002).  Both of these factors appear to promote insulin resistance in 
mice, at least in part, through elicitation of a type 1 immune responses in WAT 
(Jung and Choi, 2014; Ouchi et al., 2011).  In contrast to leptin, resistin and 
RBP4, adiponectin production by white adipocytes is decreased in the context of 
obesity (Ouchi et al., 2011).  In addition, adiponectin has insulin-sensitizing and 
anti-inflammatory effects (Gregor and Hotamisligil, 2011; Kadowaki et al., 2006; 
Lumeng and Saltiel, 2011), and loss of this anti-inflammatory signal may be one 
factor that contributes to the development of inflammation in WAT in obesity.  
Therefore white adipocytes appear to link metabolic status of mammals to 
immune responses in WAT. 
 
1.2.2  Brown adipocytes 
Although brown adipocytes can also produce adipokines, these cells differ from 
white adipocytes developmentally, functionally and anatomically.  In mice, brown 
adipocytes arise from a Myf5+ lineage and are developmentally more closely 
related to skeletal muscle cells than to white adipocytes (Kajimura et al., 2009; 
Seale et al., 2008).  The primary function of brown adipocytes in both mice and 
humans is to convert chemical energy into heat via Uncoupling protein 1 (UCP1) 
(Cannon and Nedergaard, 2004).  UCP1 is a long chain fatty acid/proton 
symporter that dissipates the mitochondrial electrochemical gradient, thereby 
uncoupling energy substrate oxidation from ATP synthesis and resulting in the 
generation of heat (Fedorenko et al., 2012; Matthias et al., 2000).  This process 
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is critical for maintaining core body and in the regulation of weight gain by 
regulating whole body energy expenditure.  In the latter case, for example, mice 
that lack UCP1 develop obesity when housed at thermoneutrality (30°C) as 
compared to UCP1-sufficient controls (Feldmann et al., 2009).  Although global 
deletion of UCP1 impairs thermogenesis in both brown and beige adipocytes, 
interscapular BAT is believed to be an important regulator of metabolic rate and 
obesity susceptibility in mice.    
 
Brown adipocytes are found in discrete brown adipose tissue (BAT) depots.  In 
mice, the largest BAT depot is present in the interscapular space and smaller 
depots are present in the axilla and along the cervical column (Bartelt and 
Heeren, 2014). In humans, brown adipocytes are abundant in newborns 
including the interscapular space (Hondares et al., 2014), whereas in lean adult 
humans brown adipocytes are reported to be present in the supraclavicular 
space of the neck and adjacent to the cervical column and heart (van Marken 
Lichtenbelt et al., 2009; Virtanen et al., 2009).  Subsequent studies have 
determined that in healthy adults supraclavicular neck BAT exhibits a gene 
expression profile and has morphologic characteristics consistent with beige 
adipocytes (Lee et al., 2014; Sharp et al., 2012; Wu et al., 2012).   
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1.3.3  Beige adipocytes 
Like brown adipocytes, beige adipocytes (also known as brown-like or brite 
adipocytes) express high levels of UCP1 and store triglyceride in one or more 
lipid droplets, giving rise to a paucilocular or multilocular cell morphology. 
However, beige and brown adipocytes differ from each other in their 
developmental and anatomic characteristics.  Brown adipocytes arise from a 
Myf5+ precursor and are developmentally related to skeletal muscle cells 
(Kajimura et al., 2009; Seale et al., 2008), whereas beige adipocytes arise from 
Myf5− precursors within WAT and are developmentally related to smooth muscle 
cells (Long et al., 2014) and/or white adipocytes (Sanchez-Gurmaches and 
Guertin, 2014).  Beige adipocytes are believed to arise from multiple 
developmental pathways, including differentiation from committed beige pre-
adipocytes as well as white-to-beige transdifferentiation in which mature white 
adipocytes are converted into a beige adipocyte (Fig. 1) (Barbatelli et al., 2010; 
Harms and Seale, 2013; Moisan et al., 2014; Sanchez-Gurmaches and Guertin, 
2014; Wang et al., 2013b; Wu et al., 2012).  This suggests that there is a close 
developmental relationship between white and beige adipocytes and that there 
may be distinct developmental pathways resulting in a heterogeneous population 
of beige adipocytes.  In mice, beige adipocytes are enriched in subcutaneous 
WAT compared to visceral fat, however beige adipocytes are elicited in both 
subcutaneous and visceral WAT (Qiu et al., 2014).  Whether beige adipocytes in 
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subcutaneous and visceral fat differ from each other developmentally or 
functionally remains unclear.  
 
Beige adipocytes are elicited in response to environmental stimuli including 
exposure to cold environmental temperatures and are activated or induced to 
differentiate in response to a range of small molecules and hormones, including 
norepinephrine (Qiu et al., 2014; Rao et al., 2014), adenosine (Gnad et al., 
2014), lactate (Carriere et al., 2014), β-aminoisobutyric acid (BAIBA) (Roberts et 
al., 2014), prostaglandin E2 (PGE2) (Madsen et al., 2010), parathyroid hormone-
related protein (PTHrp) (Fisher et al., 2012), bone morphogenetic protein 4 
(BMP4) (Qian et al., 2013), BMP7 (Schulz et al., 2011), fibroblast growth factor 
21 (FGF21) (Fisher et al., 2012), irisin (Wu et al., 2012) and meteorin-like (Rao et 
al., 2014).  Although many factors are known to promote beige adipocyte 
differentiation or function, it remains unknown whether these factors act on 
different subsets of beige adipocytes or whether they elicit developmentally or 
functionally distinct subsets of beige adipocytes.  In addition, it is unclear whether 
these factors coordinately regulate beige adipocyte function.   
 
Nonetheless, recent studies indicate that selective deletion of beige but not 
brown adipocytes results in impaired glucose homeostasis and increased 
susceptibility to weight gain in response to high fat diet feeding (Cohen et al., 
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2014).  Conversely, deletion of LGR4 results in enhanced beige adipocyte 
development and function and is associated with increased metabolic rate and 
decreased obesity (Wang et al., 2013a).  Further, 129Sv mice that are resistant 
to diet-induced obesity exhibit increased beiging of WAT compared to C57BL/6 
mice that are susceptible to diet-induced obesity (Shabalina et al., 2013).  
Feeding 129Sv mice a HFD supplemented with indomethacin blunted the 
PGE2/beige adipocyte pathway and resulted in increased accumulation of WAT 
compared to controls fed a HFD without indomethacin (Madsen et al., 2010).  In 
the context of human obesity, the incidence of brown/beige adipose tissue 
(Sharp et al., 2012) is significantly decreased in obese patients compared to lean 
patients (Saito et al., 2009), and ephedrine-induced activation of this tissue is 
impaired in human obesity (Carey et al., 2013).  In addition, UCP1 expression 
was found to be higher in cultured beige adipocytes from lean patients as 
compared to obese patients, suggesting that beige adipocyte differentiation or 
activation is impaired in human obesity (Carey et al., 2014).  These studies 
indicate that beige adipocytes confer beneficial metabolic properties and that loss 
of beige fat function may have deleterious metabolic effects including increased 
susceptibility to weight gain. 
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1.3  Immune cell composition and function in lean white adipose 
tissue 
White adipose is a heterogeneous tissue comprised of multiple cell types 
including a diverse array of immune cells.  In the steady state, these immune 
cells tend to be associated with the type 2 immune axis and include alternatively 
activated macrophages (AAMacs), eosinophils, group 2 innate lymphoid cells 
(ILC2s), invariant natural killer T (iNKT) cells, T helper type 2 (Th2) cells, 
regulatory T (Treg) cells and other immune cell populations that communicate with 
each other and participate in cross-talk with adipocytes.  As discussed below, the 
interface between immune cells and adipocytes contributes to the regulation of 
lipid storage, glucose utilization, redox balance and energy expenditure (Fig. 2).  
However, in the context of obesity, type 2 immune cells in WAT become 
dysregulated and, in some cases, acquire a pro-inflammatory phenotype that 
exacerbates adipose tissue inflammation with deleterious effects on metabolism.  
In this section, we discuss emerging concepts in the composition of function of 
immune cells in WAT at steady state and how changes in these immune cells in 
obesity contribute to metabolic dysfunction. 
 
1.3.1  The IL-4/Alternatively activated macrophage pathway 
Alternatively activated macrophages (AAMac) are IL-4- and IL-13-dependent 
cells that require Signal transducer and activator of transcription 6 (STAT6) to 
maintain an alternative activation state that is distinct from the classical activation 
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state induced by interferon-γ (IFNγ) (Gordon and Martinez, 2010; Hill et al., 2014; 
Martinez et al., 2009; Odegaard and Chawla, 2011; Olefsky and Glass, 2010).  
AAMacs are critical for protective immunity against helminth pathogens and are 
associated with pathologic allergic inflammation in the lung (Gordon and 
Martinez, 2010; Martinez et al., 2009), and recent studies have implicated 
AAMacs in the regulation of metabolic homeostasis (Hill et al., 2014; Odegaard 
and Chawla, 2011; Olefsky and Glass, 2010).  Early studies linking AAMacs to 
metabolism demonstrated that macrophage-specific deletion of Peroxisome 
proliferator-associated receptor (PPAR)-γ results in decreased AAMacs in WAT 
in association with increased weight gain, elevated fat accumulation, impaired 
glucose uptake and insulin resistance following HFD feeding (Odegaard et al., 
2007).  In addition, deletion of PPAR-δ in leukocytes also impaired AAMac 
responses and was associated with increased adiposity and insulin resistance 
(Odegaard et al., 2008).  These loss of function studies are complemented by 
gain-of-function approaches indicating that administration of exogenous IL-4 to 
mice to boost AAMac responses protected mice from HFD-induced obesity and 
insulin resistance (Chang et al., 2012; Ricardo-Gonzalez et al., 2010).  Together, 
these studies identified a critical role for the IL-4/AAMac axis in the regulation of 
metabolic homeostasis.  
 
Emerging work has revealed that AAMacs employ a diverse functional repertoire 
to regulate metabolism.  For example, a subset of AAMacs in WAT expresses 
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genes involved in iron handling and has the capacity to store large amounts of 
iron in lean mice (Orr et al., 2014).  The capacity of these specialized AAMacs to 
store iron is diminished in the setting of obesity, leading to accumulation of iron in 
adipocytes (Orr et al., 2014) and iron-initiated production of highly toxic lipid 
aldehydes that damage cellular proteins, impair adipocyte insulin sensitivity and 
lead to mitochondrial dysfunction (Curtis et al., 2010; Curtis et al., 2012). 
Therefore it appears that specialized iron-storing AAMacs have an essential role 
in regulating iron homeostasis in WAT to maintain optimal glucose metabolism 
and mitochondrial function at steady state, and that dysregulation of these cells 
in obesity may have deleterious effects on glucose and energy homeostasis.  
Consistent with this, treatment of obese mice with the iron chelator deferoxamine 
is associated with improved glucose tolerance, decreased body weight and fat 
mass, and less inflammation in fat compared to obese controls that received 
vehicle (Tajima et al., 2012). 
 
In addition, AAMacs from adipose are capable of producing catecholamines such 
as norepinephrine that act on adipocytes via adrenergic receptors to stimulate 
lipolysis, activate mitochondrial biogenesis and upregulate expression of 
Uncoupling protein 1 (UCP1) (Fig. 2 and Fig. 3) (Liu et al., 2014; Nguyen et al., 
2011; Qiu et al., 2014; Rao et al., 2014).  Recent studies suggest that AAMacs 
are critical for optimal brown and beige adipocyte responses (Nguyen et al., 
2011; Qiu et al., 2014; Rao et al., 2014).  Mice that lack IL-4 and IL-13 (Il4/13−/−); 
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the shared receptor for these cytokines, IL-4Rα (Il4ra−/−); or STAT6, a 
transcription downstream of IL-4Rα signaling (Stat6−/−) have defective AAMac 
responses (Martinez et al., 2009) and exhibit decreased upregulation of UCP1 
expression in BAT and impaired defense of core body temperature following 
acute exposure to cold environmental temperatures (Nguyen et al., 2011).  IL-4 
was shown to activate AAMacs to produce catecholamines such as 
norepinephrine (NE) that act on the β3 adrenergic receptor (β3AR) to stimulate 
lipolysis, elicit mitochondrial biogenesis and activate UCP1 in BAT (Nguyen et 
al., 2011).   
 
However IL-4/IL-4Rα interactions do not appear to be required for BAT 
responses in the context of chronic exposure to severe cold environmental 
temperatures over a period of 3 days (Qui et al., 2014).  In this context, AAMacs 
in WAT produce NE to promote beiging of WAT (Fig. 3) (Qiu et al., 2014; Rao et 
al., 2014).  Mice lacking IL4/13, STAT6 or IL-4Rα failed to undergo optimal 
beiging of WAT and had decreased metabolic rate compared to wildtype controls 
in the setting of chronic cold exposure (Qiu et al., 2014; Rao et al., 2014).  This 
phenotype appears to be mediated by macrophage-intrinsic production of 
norepinephrine, as mice that lack the rate-limiting step of catecholamine 
synthesis, tyrosine hydroxylase (Th), in LysM-Cre-expressing cells such as 
macrophages exhibit impaired beige fat development and exhibit a 10-15% 
decrease in whole body oxygen consumption in the setting of chronic exposure 
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to mild (room temperature) or severe (5°C) cold environmental temperatures (Qiu 
et al., 2014).  This defect in metabolic rate suggests that AAMac-derived 
catecholamines might also be important for limiting weight gain.  Consistent with 
this, mice that lack Receptor interacting protein 140 (RIP140) had increased 
AAMac responses in WAT and elicitation of beiging that was associated with 
protection from diet-induced obesity (Liu et al., 2014).  In addition, treatment of 
mice with exogenous IL-4 elicits beiging and increases oxygen consumption 
levels in an UCP1-dependent manner, effects that are associated with protection 
from diet-induced obesity (Chang et al., 2012; Qiu et al., 2014; Ricardo-Gonzalez 
et al., 2010).   
 
1.3.2  Sources of IL-4 in WAT: eosinophils and invariant natural killer T 
(iNKT) cells  
The importance of AAMacs in regulation of metabolic homeostasis led to studies 
of the sources of IL-4 in WAT.  Using the 4get mouse, a reporter strain that 
identifies IL-4-competent cells, it was determined that eosinophils are an 
abundant immune cell population in WAT and are an important source IL-4 in this 
compartment at steady state (Wu et al., 2011).  Eosinophils are recruited to WAT 
in the setting of chronic exposure to cold environmental temperatures, and 
ΔDblGata1 mice that lack eosinophils exhibit defective beiging of WAT (Qiu et 
al., 2014; Rao et al., 2014).  In addition, eosinophils are decreased in WAT of 
HFD-fed and genetically obese ob/ob mice (Wu et al., 2011).  Mice lacking 
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eosinophils or IL-5, which is required for eosinophil homeostasis (Rosenberg et 
al., 2013; Rothenberg and Hogan, 2006), develop more severe obesity and 
insulin resistance than wildtype controls in association with dysregulated AAMac 
responses (Wu et al., 2011). Further, transgenic mice that constitutively 
overexpress IL-5 or that were infected with helminth pathogens had increased 
eosinophil accumulation in WAT and were protected from diet-induced obesity 
and insulin resistance (Wu et al., 2011; Yang et al., 2013b).  This indicates that 
eosinophils are important regulators of metabolic homeostasis in WAT.  Although 
eosinophils appear to promote AAMac responses in WAT through production of 
IL-4 (Wu et al., 2011; Qiu et al., 2014), whether eosinophils have other functions 
in WAT such as tissue remodeling remains unknown. 
 
In addition to eosinophils, invariant natural killer T (iNKT) cells that express lipid 
antigen-specific T cell receptor variants appear to be an important source of IL-4 
and IL-13 in WAT (Hams et al., 2013; Lynch et al., 2012).  iNKT cells in WAT 
produce more IL-4 and IL-10 and less IFN-g than do iNKT cells in the liver and 
spleen (Lynch et al., 2012), suggesting that iNKT cells in WAT are in an 
“alternative activation” state.  Consistent with this, recent work has shown that 
mammals produce endogenous αGalCer and that these endogenous lipid 
antigens promote production of type 2 cytokines by iNKT cells (Kain et al., 2014), 
and that adipocytes can present lipid antigen to iNKT cells (Huh et al., 2013). 
iNKT cells are decreased in murine and human obesity, and surgical or dietary 
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treatment of obesity restores iNKT cells in WAT (Lynch et al., 2012).  Jα18-
deficient mice that lack iNKT cells exhibit increased body weight and adiposity 
when fed a HFD compared to wildtype controls, and CD1d-deficient mice that 
cannot present lipid antigen to iNKT cells develop spontaneous obesity on a low 
fat diet (Lynch et al., 2012). In addition, mice lacking iNKT cells had more severe 
glucose intolerance and increased pro-inflammatory macrophages in WAT 
(Lynch et al., 2012), suggesting that iNKT cells are essential for limiting 
inflammatory responses in the setting of obesity.  Adoptive transfer of iNKT cells 
induces weight loss and decreases adipocyte size while improving insulin 
resistance in HFD-fed mice (Hams et al., 2013; Lynch et al., 2012), and 
treatment of HFD mice with αGalCer recapitulates these effects in an iNKT-
dependent manner by increasing IL-4 and IL-10 production by iNKT cells (Lynch 
et al., 2012).  Therefore, eosinophils and iNKT cells may be important sources of 
IL-4 or other factors that support AAMac function or that directly regulate 
metabolic homeostasis to limit obesity and insulin resistance. 
 
1.3.3  The IL-33/Group 2 innate lymphoid cell pathway 
Group 2 innate lymphoid cells (ILC2s) are a recently described immune cell type 
(Moro et al., 2009; Price et al., 2010; Neill et al. 2010) that controls eosinophil 
and AAMac responses (Molofsky et al., 2013; Nussbaum et al., 2013).  ILC2s are 
members of a broader family of ILCs that comprise T-bet-dependent Group 1 
ILCs that produce IFN-γ; GATA-3-dependent ILC3s that produce IL-5, IL-13 and 
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amphiregulin; and RORγt-dependent ILC3s that produce IL-17A and IL-22 (Kim, 
2014; Monticelli et al., 2012; Sonnenberg et al., 2013; Spits et al., 2013; Spits 
and Cupedo, 2012).  In barrier surfaces such as the gut and lung, ILC2s respond 
to epithelial-derived cytokines IL-33, IL-25 and thymic stromal lymphopoietin 
(TSLP) to initiate type 2 immune responses that protect against helminth 
infection or that promote pathologic allergic inflammation (Kim, 2014; Monticelli et 
al., 2012; Sonnenberg et al., 2013; Spits et al., 2013; Spits and Cupedo, 2012).  
ILC2s were recently shown to be present in murine WAT, where these cells 
constitutively produce the effector cytokines IL-5 and IL-13 to maintain eosinophil 
and AAMac responses, respectively, in WAT (Molofsky et al., 2013).  Strikingly, 
IL-5-deficient mice exhibit decreased energy expenditure and increased obesity 
compared to IL-5-sufficient controls (Molofksy et al., 2013; Wu et al., 2011). 
Recent studies showed that antibody-mediated depletion of ILC2s is associated 
with increased weight gain and more severe insulin resistance in mice fed a high 
fat diet (Hams et al., 2013), and transferring IL-25-elicted ILC2s is sufficient to 
promote weight loss in diet-induced obese mice (Hams et al., 2013).  This 
suggests that ILC2s negatively regulate the development of obesity, although the 
mechanisms of this remain poorly understood.  One possibility is that ILC2s limit 
adiposity via regulation of the eosinophil/IL-4/AAMac pathway to elicit beiging. 
Future studies will be required to investigate the mechanisms by which ILC2s 
regulate metabolic homeostasis. 
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The cytokine IL-33 is critical for stimulating proliferation and activation of ILC2s 
(Kim et al., 2014; Molofsky et al., 2013; Monticelli et al., 2011; Moro et al., 2010; 
Neill et al., 2010; Price et al., 2010) and is expressed at higher levels in WAT of 
obese mice and humans compared to non-obese controls (Zeyda et al., 2013).  
Given that ILC2s are decreased in murine obesity (Molofsky et al., 2013), this 
suggests that in the obese state ILC2s may be hypo-responsive to IL-33 or have 
altered cell death, proliferation or migration.  IL-33 was recently shown to be 
critical for protecting mice from obesity (Miller et al., 2010).  Mice lacking the IL-
33R exhibit increased obesity and exacerbated impairments in glucose 
homeostasis following HFD feeding, and treatment of genetically obese ob/ob 
mice with recombinant IL-33 limits adiposity and improves glucose metabolism in 
association with enhanced AAMac responses in WAT (Miller et al., 2010). 
 
1.3.4  CD4+ T helper cells and regulatory T cells 
In addition to regulating the ILC2/eosinophil/AAMac pathway, IL-33 also acts on 
adaptive immune cells such as Th2 cells (Molofsky et al., 2013) and regulatory T 
cells (Tregs) (Schiering et al., 2014).  Although Th2 cells are relatively rare in 
WAT (Molofsky et al 2013) and remain poorly understood in the context of 
obesity, Tregs in WAT have been shown to be unique members of the Treg pool 
exhibiting uniquely elevated expression of PPARγ, Foxp3 and IL-10 and are 
dysregulated in obese mice and humans (Cipolletta et al., 2012; Deiuliis et al., 
2011; Feuerer et al., 2009).  Tregs in WAT contribute to the maintenance of insulin 
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sensitivity in WAT by limiting inflammation and producing insulin-sensitizing 
factors such as IL-10 (Cipolletta et al., 2012; Feuerer et al., 2009; Ilan et al., 
2010).  In obesity, Tregs are decreased in both mice and humans (Cipolletta et al., 
2012; Feuerer et al., 2009; Wagner et al., 2013), and this decrease in Tregs may 
be due to aberrant WAT iNKT cell responses in obese WAT (Lynch et al., 2014).  
iNKT cells in WAT produce IL-2 to sustain Tregs and are an additional source of 
IL-10 (Lynch et al., 2014; Lynch et al., 2012).  IL-10 suppresses Monocyte 
chemotactic protein-1 (MCP-1) expression by adipocytes to limit inflammatory 
macrophage infiltration of WAT and inhibits the ability of tumor necrosis factor-α 
(TNF-α) to downregulate GLUT-4 expression and impair insulin action in 
adipocytes (Lumeng et al., 2007).  Interestingly, recent studies indicate that the 
anti-diabetic class of drugs known as thiazoladinediones (TZD), which are PPAR-
gamma agonists, ameliorate insulin resistance in obese mice via their effects on 
Tregs (Cipolletta et al., 2012).  Therefore promoting Treg responses may be a 
useful strategy to treat or prevent type 2 diabetes. 
 
1.4  Immune cell responses in white adipose tissue in obesity 
In obesity, white adipose tissue undergoes metabolic and inflammatory changes. 
As white adipocytes accumulate triglycerides and become hypertrophic, the 
vasculature in WAT becomes rarified leading to hypoxia and oxidative stress 
(Curtis et al., 2010; Pasarica et al., 2009).  These changes are associated with 
increased adipocyte cell death and elevated production of adipocyte-derived 
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inflammatory mediators, including the adipokines leptin, resistin and RBP4 (Attie 
and Scherer, 2009; Greenberg and Obin, 2006; Lazar, 2007; McNelis and 
Olefsky, 2014; Osborn and Olefsky, 2012; Ouchi et al., 2011).  As discussed 
below, these and other pro-inflammatory factors initiate a type 1 immune 
response in obese WAT that is characterized by increased accumulation of CD4+ 
Th1 cells, CD8+ cytotoxic T cells, pro-inflammatory classically activated 
macrophages (Fig. 4). These changes are discussed in this section. 
 
1.4.1  Adipocytes, macrophages and type 1 cytokine-associated T cells 
participate in a proinflammatory positive-feedback loop in obesity 
In obesity adipocyte-derived inflammatory mediators such as monocyte 
chemotactic protein (MCP-1), CXCL12, prostaglandins, leukotrienes and other 
factors are increased and promote classically activated monocyte/macrophage 
activation, proliferation and infiltration of white adipose tissue (Amano et al., 
2014; Nomiyama et al., 2007; Oh et al., 2012; Weisberg et al., 2003).  These 
cells engulf dying or dead adipocytes, forming crown-like structures (CLS) that 
are characterized morphologically as a ring of macrophages and other immune 
cells surrounding an adipocyte (Murano et al., 2008; Ouchi et al., 2011).  The 
formation of CLS may be an adaptive mechanism to scavenge cellular debris or 
to limit the release of toxic lipid species when adipocytes undergo cell death, via 
phagocytosis.  However, in addition to their phagocytic roles in CLS, classically 
activated macrophages in WAT of obese mice produce IL-1β, TNF-α, IFN-γ and 
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IL-6 among other factors that potentiate the type 1 inflammatory response 
(Lumeng et al., 2007; Nguyen et al., 2007; Zeyda et al., 2010).  These cytokines 
act directly on adipocytes and other cell types in distant tissues such as skeletal 
muscle and liver to inhibit insulin-dependent glucose uptake (Exley et al., 2014; 
Gregor and Hotamisligil, 2011; Jin et al., 2013; Osborn and Olefsky, 2012).  This 
pro-inflammatory process is therefore associated with the development of insulin 
resistance by promoting chronic low-grade type 1 inflammation.   
 
The accumulation of macrophages in obese WAT also appears to be regulated 
by CD8+ T cells (Rausch et al., 2008).  These adaptive immune cells are 
recruited to WAT before infiltration by pro-inflammatory macrophages in the 
setting of high fat diet feeding (Nishimura et al., 2009).  Deletion of CD8+ T cells 
decreases macrophage accumulation in WAT of obese mice and ameliorates 
obesity-associated insulin resistance, and adoptive transfer of CD8+ T cells to 
mice fed a HFD is sufficient to promote macrophage infiltration of WAT and 
exacerbate insulin resistance (Nishimura et al., 2009).  In the setting of HFD 
feeding, CD8+ T cells produce IFN-γ that has multiple effects on immune cells in 
WAT (Revelo et al., 2014).  IFN-γ acts on macrophages to upregulate expression 
of pro-inflammatory effector cytokines and to increase expression of Major 
histocompatibility complex class II (MHC II) (Schroder et al., 2004).  This 
promotes macrophage antigen presentation to CD4+ T cells and incudes Th1 
polarization and proliferation (Cho et al., 2014; Morris et al., 2013). T-bet-
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dependent Th1 cells produce TNF-α and IFN-γ further potentiate insulin 
resistance in WAT (Cho et al., 2014; Morris et al., 2013; Stolarczyk et al., 2013).  
Thus, the CD8+ T cell/classically activated macrophage pathway in WAT appears 
to be critical for downstream T helper type 1 (Th1) cell responses.    
 
Adipocytes also appear to directly contribute to Th1 cell responses in obesity.  
With increased triglyceride deposition, adipocytes upregulate their expression of 
leptin, a hormone that limits food intake, as a compensatory mechanism to guard 
against overly rapid weight gain (Allison and Myers, 2014).  While this is a 
beneficial response to maintain energy homeostasis, in WAT leptin acts on CD4+ 
T cells to induce Th1 polarization and IFN-γ expression to drive a pro-
inflammatory immune response that limits insulin sensitivity (Deng et al., 2013).  
In turn, IFN-γ upregulates CIITA and MHC-II expression in adipocytes (Deng et 
al., 2013) and macrophages (Cho et al., 2014; Morris et al., 2013) to adipocyte 
antigen presentation to Th1 cells.  These MHC-II-mediated inflammatory 
changes in obesity are critical drivers of insulin resistance (Cho et al., 2014; 
Deng et al., 2013).  Therefore it appears that adipocytes, macrophages, CD8+ T 
cells and CD4+ Th1 cells participate in a pro-inflammatory positive-feedback loop 
with deleterious consequences for WAT inflammation and glucose metabolism. 
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1.4.2  Alternatively activated macrophages acquire a classical activate state 
in obesity and potentiate type 1 inflammation in WAT 
As discussed above, AAMacs have critical roles for regulating metabolic 
homeostasis in WAT at steady state.  In obesity, however, AAMacs appear to 
acquire a pro-inflammatory M1-like phenotype that contributes to the 
development in type 1 inflammatory responses in WAT.  For example, in obesity, 
AAMacs decrease their expression of IL-10 and upregulate expression of TNF-α, 
IFN-γ, IL-6 and IL-1β (Han et al., 2013; Lumeng et al., 2007; Moraes-Vieira et al., 
2014).  This phenotypic switch in AAMacs appears to be driven, at least in part, 
by retinol binding protein 4 (RBP4) that is upregulated in obesity and that impairs 
glucose homeostasis (Graham et al., 2006; Norseen et al., 2012).  AAMacs from 
transgenic mice that overexpress RBP4 exhibit upregulated expression of 
antigen presentation machinery, TNF-α and IL-1β, and polarize CD4+ T cells in 
WAT towards a Th1 phenotype characterized by increased expression of T-bet 
and IFN-γ (Moraes-Vieira et al., 2014).  Interestingly, this effect was not observed 
in the liver, suggesting a tissue-specific effect of RBP4 on antigen presenting 
cells and T cell activation (Moraes-Vieira et al., 2014).  In addition, transfer of 
RBP4-activated bone marrow-derived DCs (BMDCs) to lean recipient mice was 
sufficient to promote Th1 cell polarization in WAT and insulin resistance 
compared to unactivated BMDCs (Moraes-Vieira et al., 2014).  This suggests 
that AAMacs in WAT become dysregulated in the setting of obesity and acquire a 
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pro-inflammatory classical activation state that supports Th1 cell polarization and 
the development of insulin resistance.  
 
1.5  Perspectives and Conclusions 
Adipose tissues are diverse in their structure and function and have multiple roles 
in the regulation of energy balance and weight gain (Fig. 1).  WAT is essential for 
triglyceride storage and regulation of glucose homeostasis, and white adipocytes 
appear to link mammalian metabolic status to immune cell responses in WAT.  In 
addition, WAT contains beige adipocytes that have been shown to be key 
regulators of energy expenditure and the development of obesity.  In the lean 
state WAT is populated by type 2 cytokine-associated immune cells including 
AAMacs, eosinophils, ILC2s, Th2 and iNKT cells as well as anti-inflammatory 
cells such as Tregs.  These immune cells participate in a complex dialog to 
maintain optimal immune and adipocyte function (Fig. 2).  Although the precise 
mechanisms by which type 2 immune cells in WAT regulate each other, it 
appears that elicitation of these cell pathways is associated with increased insulin 
sensitivity, optimal adipocyte mitochondrial function and in some cases elicitation 
of beige adipocytes within WAT (Fig. 3).  Conversely, disruption of these 
immunologic pathways results in impaired adipocyte function characterized by 
insulin resistance, oxidative stress, impaired respiratory capacity and triglyceride 
deposition resulting in adipocyte hypertrophy and weight gain.  Therefore, type 2 
immune pathways in white adipose tissue appear to have protective roles that 
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support maintenance of metabolic homeostasis and limit the development of 
obesity.  This implies that eliciting type 2 immune cell pathways may be a useful 
strategy to treat or prevent obesity. 
 
However in the context of obesity, the immunologic milieu of WAT undergoes a 
dramatic shift from a type 2 to type 1 cytokine-associated inflammatory 
environment (Fig. 4).  Type 2 immune cells are decreased or dysregulated, and 
in some cases acquire a pro-inflammatory phenotype (e.g. iNKT cells and 
AAMacs).  As type 2 immune cells tend to be associated with protection against 
obesity, these alterations in type 2 cytokine-associated immunologic pathways 
may contribute to the development of obesity and associated metabolic 
dysfunction, and therefore subsequent type 1 inflammatory responses.  In 
addition, in obesity there is recruitment of various granulocytes, monocytes and 
lymphocytes to WAT.  These cell types produce cytokines such as TNF-α, IFN-γ 
and IL-1β among others that potentiate type 1 immune responses and enhance 
antigen presentation to CD4+ T cells, polarizing these cells towards a Th1 cell 
phenotype.  In turn, Th1 cells produce additional TNF-α and IFN-γ, establishing a 
positive-feedback loop resulting in chronic low-grade type 1 inflammation and 
dysregulated glucose homeostasis.  The precipitating factors that initiate type 1 
immune responses in WAT are not well understood but may be related to 
adipocyte cell death (Spalding et al., 2008), hypoxia (Sun et al., 2011), the 
generation of toxic lipid species (Muoio and Newgard, 2006), direct effects of 
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dietary lipids or carbohydrates (Calder, 2002), and translocation of commensal 
bacteria to WAT (Amar et al., 2011; Cani et al., 2007) among other factors.  The 
apparent multifactorial nature of the type 1 immune response in WAT suggests 
that targeting downstream inflammatory mediators such as IFN-γ, TNF-α or IL-1β 
might have beneficial therapeutic effects in obesity-associated insulin resistance. 
 
Finally, emerging studies have revealed complex immunomodulatory cross-talk 
between the type 1 and type 2 immune systems, where type 2 inflammation 
impairs type 1 responses and vice versa (Osborne et al., 2014; Reese et al., 
2014).  Given the dramatic shift in the immunologic landscape within obese WAT 
from a type 2 to type 1 cytokine-associated response, the effectiveness of “two-
factor” immunomodulatory therapies (e.g., neutralizing TNF-α antibody plus 
recombinant IL-4) should be explored as potential anti-obesity regimens. 
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1.6  Figures 
 
 
Figure 1.  White, beige and brown adipocytes are developmentally and 
functionally distinct cell populations.  White and beige adipocytes arise 
from a Myf5− precursor cell population that is bipotent.  These pre-
adipocytes give rise to white or beige adipocytes depending on the stimulus 
and physiologic setting.  White adipocytes are promoted by high fat diet 
feeding or obesity and by thermoneutrality (30°C in mice).  Beige 
adipocytes are elicited by β3 adrenergic receptor agonists such as 
norepinephrine or epinephrine, and are recruited within WAT in the settings 
of chronic exercise or exposure to cold environmental temperatures.  
Although white and beige adipocytes emerge from pre-adipocytes via cell 
differentiation, mature white and beige adipocytes may undergo a process 
called transdifferentiation, in which one cell type acquires phenotypic 
characteristics of the other.  In contrast, brown adipocytes arise from a 
Myf5+ precursor cell population and are present in discrete brown adipose 
tissue (BAT) depots.  Despite being developmentally distinct cell 
populations, beige and brown adipocytes are activated by similar 
physiologic stimuli, including exercise- and cold temperature-induced 
hormones and metabolites. 
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Figure 2.  Healthy white adipose tissue (WAT) is enriched in type 2 
cytokine-associated immune cells.  In the lean state, adipocytes and 
endothelial cells in WAT constitutively produces interleukin (IL)-33 that can 
act on Group 2 innate lymphoid cells (ILC2s) to induce production of IL-5 
and IL-13 that sustain eosinophil (Eos) and alternatively activated 
macrophage (AAMac) responses, respectively, in WAT.  In addition, 
eosinophils produce IL-4 that is necessary to maintain AAMac responses 
in WAT.  AAMacs have multiple functions to maintain metabolic 
homeostasis, including storing large amounts of iron, leading to 
sequestration of this pro-oxidative metal cation from adipocytes to prevent 
lipid peroxidation, oxidative damage to proteins and mitochondrial 
dysfunction.  In addition, AAMacs produce norepinephrine (NE) that acts 
on both white and beige adipocytes via the β3 adrenergic receptor to 
stimulate lipolysis and elicit beige adipocytes that increase metabolic rate.  
In addition, adipocytes present antigen to invariant natural killer T (iNKT) 
cells to elicit a unique tissue-specific anti-inflammatory phenotype 
characterized by increased production of IL-4 and IL-13, which may act on 
AAMacs, and IL-10.  In addition, lipids from adipocytes are believed to 
promote regulatory T (Treg) responses in WAT to induce production of IL-
10.  iNKT cells are critical sources of IL-2 and are necessary to sustain 
Tregs in WAT.  IL-10 production by iNKT cells and Tregs promotes insulin 
action in white adipocytes to facilitate maintenance of an insulin-sensitive 
state.  Together, these pathways contribute to metabolically healthy WAT. 
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Figure 3.  Immunologic 
mechanisms that 
regulate beiging.  In the 
context of chronic 
exposure to cold 
environmental 
temperatures or chronic 
exercise, white adipose 
tissue (WAT) and muscle 
produce the 
adipokine/myokine 
meteorin-like.  This 
hormone promotes 
eosinophil (Eos) 
accumulation in WAT.  
Whether other factors 
contribute to increased 
Eos in WAT to promote 
beiging remains unknown.  
Meteorin-like induces IL-4 
and IL-13 production by 
Eos and possibly other 
cell types. IL-4 and 
perhaps IL-13 act on 
AAMacs to stimulate 
norepinephrine (NE)/ 
epinephrine (Epi) 
production.  NE/Epi act on 
the β3 adrenergic receptor 
(β3AR) to stimulate 
beiging via differentiation 
and/or transdifferentiation 
pathways and to activate 
existing beige adipocytes, 
resulting in mitochondrial 
biogenesis, Uncoupling 
protein 1 (UCP1) 
upregulation and UCP1-
dependent increases in 
energy expenditure. 
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Figure 4.  Obese white adipose tissue (WAT) is characterized by type 1 cytokine-
associated immune responses.  In obese WAT, adipocyte hypertrophy is associated with 
hypoxia and adipocyte cell death.  Dead and neighboring adipocytes produce pro-
inflammatory signals such as Monocyte chemotractant protein 1 (MCP1), C-X-C motif 
chemokine 12 (CXCL12), Retinol binding protein 4 (RBP4) and Resistin that are associated 
with the recruitment of classically activated macrophages (MP) into WAT and MP activation.  
MP accumulation in WAT is also mediated by pro-inflammatory invariant natural killer T 
(iNKT) cells that exhibit impaired production of interleukin (IL)-10 and upregulated 
production of Tumor necrosis factor-α (TNF-α), and by CD8+ cytotoxic T cells that produce 
Interferon (IFN)-γ.  These factors also promote MP activation and upregulate Major 
histocompatibility complex class II (MHC II) on MP and adipocytes.  MHC II-mediated 
antigen presentation by MP and adipocytes stimulates polarization of CD4+ T cells towards a 
T helper type 1 (Th1) phenotype.  Supporting this process are TNF-α, IFN-γ, IL-1β and IL-6 
produced by MP cells, dysregulated alternatively activated macrophages (AAMacs), iNKT 
cells and CD8+ T cells.  In addition, leptin is upregulated in obese WAT, and this factor also 
promotes Th1 cell polarization.  MP cells, CD8+ T cells and Th1 cells collectively interact to 
form crown-like structures (CLS) to facilitate phagocytosis of dead adipocytes.  This process 
further promotes antigen presentation and type 1 immune responses, establishing a vicious 
cycle.  Type 1 cytokines such as TNF-α and IFN-γ act directly on adipocytes to impair insulin 
action, leading to insulin resistance.  Dysregulated AAMacs also produce type 1 cytokines in 
the setting of obesity to contribute to insulin resistance.  AAMacs also lose their capacity to 
store iron, resulting in redistribution of iron to adipocytes. This results in iron-initiated lipid 
peroxidation that causes reactive oxygen species (ROS) production, insulin resistance and 
mitochondrial dysfunction.  In addition, AAMacs in obese WAT promote collagen deposition 
in WAT and fibrosis, leading ultimately to exacerbated hypoxia and inflammation and 
potentiation of the type 1 immune response.  These processes occur in the setting of 
decreased abundance of regulatory T cell (Treg), Group 2 innate lymphoid cell (ILC2) and 
eosinophils (Eos) that promote insulin sensitivity and metabolic homeostasis in WAT in the 
steady state. 
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Chapter 2:  Group 2 innate lymphoid cells are 
dysregulated in human and murine obesity and are 
regulated by IL-33 
 
 
2.1 Abstract 
In obesity there is a shift from type 2 to type 1 cytokine-associated immune 
responses in white adipose tissue (WAT) that promote insulin resistance.  In 
addition, emerging studies indicate that type 2 immune cells such as eosinophils 
and alternatively activated macrophages that limit weight gain become 
dysregulated in obese WAT, suggesting that decreased type 2 immune 
responses in WAT may contribute to the development of obesity.   Group 2 
innate lymphoid cells (ILC2s) were recently identified in murine white adipose 
tissue (WAT), where they produce interleukin (IL)-5 and IL-13 to maintain 
eosinophil and AAMac responses in WAT and limit the development of obesity.  
However, ILC2s have not been identified in human adipose tissue, and the 
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factors that control ILC2 responses in WAT remain poorly characterized.  Here, 
we identify IL-33 receptor+ ILC2s in human WAT and demonstrate that 
decreased ILC2 populations in WAT are a conserved characteristic of obesity in 
humans and mice.  Employing loss-of-function studies in mice, we demonstrate 
that endogenous IL-33 is necessary to maintain normal ILC2 frequencies, 
numbers and effector cytokine production.  IL-33-deficient mice exhibited 
increased adiposity and impaired glucose homeostasis compared to IL-33-
sufficient controls.  In gain-of-function studies, administering recombinant murine 
(rm)IL-33 to mice resulted in increased ILC2 accumulation in WAT and 
ameliorated obesity and glucose intolerance in mice fed a HFD.  rmIL-33 
treatment was associated with increased caloric expenditure without affecting 
food intake, suggesting that IL-33 treatment influences body weight by regulating 
metabolic rate.  Collectively, these data indicate that IL-33 is critical for regulating 
ILC2 responses in WAT and for limiting adiposity, and suggest that the IL-
33/ILC2 pathway may be dysregulated in the context of human and murine 
obesity. 
 
2.2 Introduction 
Obesity is an increasingly prevalent metabolic disease characterized by 
accumulation of excess adipose tissue and insulin resistance (Ogden et al., 
2012; Pi-Sunyer, 1999).  Genetic and environmental factors contribute to the 
development of obesity, and emerging studies indicate that the immune system 
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also regulates weight gain and insulin resistance (Bouchard, 2008; Gregor and 
Hotamisligil, 2011; Lumeng and Saltiel, 2011; Odegaard and Chawla, 2013b; 
Osborn and Olefsky, 2012).  This implies that dissecting the complex interactions 
between immune and metabolic systems will be important for understanding the 
biology underlying obesity and how current and future therapeutics might 
influence metabolism.   
 
Recent studies indicate that type 2 cytokine-associated immune cells such as 
alternatively activated macrophages (AAMacs) and eosinophils can regulate 
metabolic homeostasis.  For example, mice with impaired AAMac responses are 
more susceptible to diet-induced obesity than mice with normal AAMac 
responses (Odegaard et al., 2007; Odegaard et al., 2008; Ricardo-Gonzalez et 
al., 2010).  In addition, treatment of mice with recombinant IL-4, which induces 
and maintains AAMac polarization (Martinez et al., 2009), protects mice from the 
development of obesity (Chang et al., 2012; Ricardo-Gonzalez et al., 2010).  
Eosinophils are the dominant IL-4-producing cell type in white adipose issue 
(WAT) (Wu et al., 2011).  These innate immune cells are dependent on IL-5 and 
are traditionally viewed as being end-stage effector cells with critical roles in 
protective immunity to parasitic helminth infection and pathologic roles in allergic 
lung inflammation (Rosenberg et al., 2013; Rothenberg and Hogan, 2006).  
However in WAT, eosinophils are abundant immune cells with homeostatic 
functions that control weight gain (Wu et al., 2011).  For example, mice lacking 
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eosinophils or IL-5 develop more severe obesity than wildtype controls, and IL-5-
transgenic hypereosinophilic mice are protected from diet-induced obesity 
(Molofsky et al., 2013; Wu et al., 2011).  Further, parasitic helminth infection with 
the hookworm Nippostrongylus brasiliensis results in eosinophil accumulation in 
WAT and decreases obesity in mice fed a high fat diet (HFD) (Wu et al., 2011; 
Yang et al., 2013b).  These studies indicate that eosinophils, a terminal type 2 
effector cell population, are important for regulation of weight gain in mice. 
 
Group 2 innate lymphoid cells (ILC2s) are recently described innate immune cells 
that initiate type 2 immune responses by producing large amounts of the type 2 
cytokines IL-5 and IL-13 to control eosinophil and AAMac responses (Molofsky et 
al., 2013; Moro et al., 2010; Neill et al., 2010; Nussbaum et al., 2013; Price et al., 
2010).  ILC2s are dependent on the transcription factors Inhibitor of DNA binding 
2 (Id2) and T cell factor 1 (TCF1, also known as TCF7) as well as the common 
gamma chain (γc, also known as IL-2Rγ) among other factors (Monticelli et al., 
2011; Moro et al., 2010; Neill et al., 2010; Yang et al., 2013a).  In addition, ILC2s 
are developmentally and functionally dependent on GATA binding protein 3 
(GATA-3), which is essential for IL-5 and IL-13 production by ILC2s (Furusawa et 
al., 2013; Klein Wolterink et al., 2013; Mjosberg et al., 2012).  ILC2s are activated 
by the epithelial cell-derived cytokines IL-33, IL-25 and thymic stromal 
lymphopoietin (TLSP) to elicit type 2 immune responses important for helminth 
parasite expulsion and allergic inflammation (Hong et al., 2014; Kim et al., 2013; 
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Kim et al., 2014; McSorley et al., 2014; Moro et al., 2010; Neill et al., 2010; Price 
et al., 2010; Roediger et al., 2013; Yang et al., 2013a).   
 
Recent studies have also implicated ILC2s in the regulation of obesity (Hams et 
al., 2013; Molofsky et al., 2013).  Mice fed a HFD for 12 weeks are reported to 
have decreased frequencies and numbers of ILC2s in association with impaired 
eosinophil and AAMac responses in WAT (Molofsky et al., 2013).  In addition, 
treatment of HFD-fed lymphocyte-deficient mice with anti-CD90.2 monoclonal 
antibody was associated with decreased ILC2s in WAT as well as increased 
weight gain and worsened insulin resistance compared to mice receiving control 
immunoglobulin (Hams et al., 2013).  Gain-of-function studies also indicate that 
adoptive transfer of IL-25-elicited ILC2s sort-purified from peritoneal exudate 
cells (PECs) is associated with weight loss in HFD-fed mice (Hams et al., 2013).  
Collectively, these studies indicate that ILC2s may be dysregulated in obese 
mice and that ILC2s may act to limit the development of obesity.   However, 
ILC2s have not been identified in human WAT, and whether ILC2s are 
dysregulated in human obesity remains unknown.  In addition, the upstream 
factors that regulate ILC2 responses in WAT remain poorly understood. 
 
Data presented in this Chapter identify IL-33 receptor (IL-33R)+ ILC2s in human 
and murine WAT and demonstrate that ILC2 populations are decreased in both 
human and murine obesity.  It is also shown that IL-33 critically regulates ILC2 
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responses in WAT and the development of obesity in mice.  IL-33-deficient mice 
had decreased frequencies and numbers of ILC2s in epididymal (E)-WAT and 
inguinal i(WAT) and exhibited impaired ILC2-derived IL-5 and IL-13 expression.  
When fed a normal low fat diet, IL-33-deficient mice developed spontaneous 
weight gain and accumulation of fat mass and were insulin resistant.  
Additionally, treatment of HFD-fed mice with recombinant IL-33 increased ILC2 
accumulation in WAT and abrogated HFD-induced increases in fat mass and 
glucose intolerance.  IL-33 treatment decreased whole body adiposity in lean 
mice, and this was associated with increased caloric expenditure.  Collectively, 
results presented in this Chapter indicate that decreased ILC2 populations in 
WAT is a conserved characteristic of obesity in mice and humans and implicate 
the IL-33/ILC2 axis in the regulation of metabolic rate to limit the development of 
obesity in mice. 
 
 
2.3 Methods 
2.3.1  Mice   
C57BL/6 and Rag1−/− mice were obtained from Jackson Labs. Il33+/+ mice were 
obtained from Taconic, and Il33−/− mice were obtained from Amgen Inc via 
Taconic. Id2-/- bone marrow chimeras (Monticelli et al., 2011) and Tcf7-/- mice 
(Yang et al., 2013a) were generated as described previously.  For Id2-deficient 
bone marrow chimeras, 10-20 x 106 bone marrow cells from congenically marked 
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Id2+/+ (CD45.1+ CD45.2−) or Id2−/− (CD45.1− CD45.2+) fetal liver chimeras were 
transferred by intravenous injection into lethally irradiated wildtype hosts (900 
RAD) of a unique congenic marker combination (CD45.1+ CD45.2+) (Monticelli et 
al., 2011).  All mice were males and had ad libitum access to food and water and 
were maintained in a specific pathogen free facility with a 12h:12h light:dark 
cycle (lights on at 7:00 AM, lights off at 7:00 PM).  Animals were randomly 
assigned to groups of n=3-5 mice per group per experiment, and at least two 
independent experiments were performed throughout.  In all in vivo experiments, 
a single technical replicate per mouse was performed except in glucose 
homeostasis tests described below, in which 2-4 technical replicates were 
performed per mouse for each time point.  For all in vitro experiments, 2-3 
technical replicates were performed in each independent experiment.  Sample 
sizes in each independent experiment were selected to have power of at least 
90% using published sample size/power formulas (Brestoff and Van den Broeck, 
2013). All experiments were carried out under the guidelines of the Institutional 
Animal Care and Use Committee at the University of Pennsylvania. 
 
2.3.2  Human samples 
Subcutaneous white adipose tissue (S-WAT) from the abdominal region was 
obtained from human donors via the New York Human Organ Donor Network 
(NYODN) and via the Cooperative Human Tissue Network (CHTN) Eastern 
Division, University of Pennsylvania. NOYDN samples were from recently 
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deceased organ donors at the time of organ acquisition for clinical transplantation 
through an approved research protocol and MTA with the NYODN. All NYODN 
donors were free of cancer and were Hepatitis B-, Hepatitis C-, and HIV-
negative. Tissues were collected after the donor organs were flushed with cold 
preservation solution and clinical procurement process was completed.  Samples 
from CHTN were collected from non-deceased adults undergoing surgery for 
other purposes (e.g. elective panniculectomies), and were harvested from 
discarded connective tissue by CHTN staff.  All human samples from NYODN 
and CHTN were stored in DMEM on ice or at 4°C for 24-48 hours before 
processing.   
 
Donors were defined as non-obese if their body mass index (BMI) was < 30.0 
kg/m2 (n=7) or obese if their BMI was ≥ 30.0 kg/m2 (n=7).  Sample sizes per 
group were selected to have power >95% using published sample size/power 
formulas (Brestoff and Van den Broeck, 2013).  There were no differences in the 
proportion of donors from NYODN or CHTN between non-obese and obese 
groups (Table 1). ILC2 frequencies were also compared for all characteristics 
shown in Table 1, and those characteristics that had a P-value < 0.10 were 
interrogated to test whether they could explain the differences in ILC2 
frequencies observed between non-obese vs obese donors. The human samples 
from NYODN do not qualify as “human subjects” research, as confirmed by the 
Columbia University IRB, and the human samples from CHTN were de-identified 
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and were not obtained for the specific purpose of these studies and therefore are 
not considered “human subjects” research. 
 
2.3.3  Rodent chow and diet-induced obesity  
In all experiments, mice had ad libitum access to food and water. Where 
indicated, mice were fed a control diet (CD, 10% kcal fat, Research Diets, New 
Brunswick, New Jersey) or high fat diet (HFD, 45% or 60% kcal fat as indicated, 
Research Diets) for the indicated period of time starting at 6-8 weeks of age.  
CD, 45% HFD and 60% HFD were gamma-irradiated (10-20 kGy) and stored at 4 
°C under dry conditions until use, and rodents were provided fresh chow weekly.  
In all experiments that did not employ CD or HFD, mice were fed a standard 
autoclavable rodent chow (5% kcal fat, #5010, Lab Diets, St. Louis, Missouri) that 
had been autoclaved and allowed to cool overnight before use.  
 
2.3.4  In vivo cytokine treatments  
Mice were administered 12.5 µg/kg carrier-free recombinant murine IL-33 (rmIL-
33, R&D Systems, Minneapolis, Minnesota) in sterile phosphate buffered saline 
(PBS) by intraperitoneal (i.p.) injection daily for the indicated number of days.  In 
HFD studies, mice were treated with 12.5 µg/kg recombinant murine IL-33 or 
PBS once every 4 days by i.p. injection. All injections were performed between 
the hours of 4:00 PM and 7:00 PM. 
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2.3.5  In vivo metabolic phenotyping  
Mice were single-housed in an OxyMax Comprehensive Laboratory Animal 
Monitoring System (CLAMS, Columbus Instruments, Columbus, Ohio) for 24 
hours.  Mice were acclimated to the CLAMS cages for 24 hours before 
measurements commenced.  Caloric expenditure (kcal/hour) was measured by 
indirect calorimetry.  Food intake was also measured throughout the 24 hour 
period.  Fat mass and adiposity were measured by 1H-nuclear magnetic 
resonance (NMR) spectroscopy.   
 
For glucose tolerance tests, mice were fasted overnight for 14-16 hours (h) and 
injected with 2 g/kg D-glucose by i.p. injection. Blood glucose values were 
measured just prior to injection (time 0) and at 20, 40, 60, 90 and 120 minutes 
(min) post-injection. For insulin tolerance tests, mice were fasted for 4-6h and 
then injected with bovine insulin (0.5 U/kg). Blood glucose values were measured 
just prior to injection (time 0) and at 20, 40 and 60 min post-injection.  To 
measure fasting blood glucose and insulin concentrations, mice were fasted 
overnight for 14-16 hours, and blood glucose values were measured followed by 
collection of approximately 20-30 µL blood for serum insulin concentration 
determination using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem).  
Homeostatic model assessment of insulin resistance (HOMA-IR) index values 
were calculated as described previously (Matthews et al., 1985). All blood 
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glucose measurements were performed using FreeStyle Lite handheld 
glucometer (Abbott) in duplicate or triplicate. 
 
2.3.6  Adipocyte area quantification.   
Inguinal white adipose tissue (iWAT) sections were H&E stained and imaged at 
40X magnification.  White adipocyte area was calculated using ImageJ software 
by drawing ellipses circumscribing white adipocytes.  The scale was set to 8 
pixels per micron based on the pixel length of a 100 µm scale bar at 40X 
magnification.  Two-to-three images, each from a different area of a given 
sample, were captured per animal. Adipocyte area was measured in 10-20 
adipocytes per image (25-40 adipocytes per mouse) and averaged on a per 
mouse basis.  
 
2.3.7  Isolation of immune cells from adipose 
Murine epididymal white adipose tissue (E-WAT), inguinal WAT (iWAT) or brown 
adipose tissue (BAT) or human subcutaneous abdominal WAT were harvested 
and dissected so as to be free of reproductive tissues, lymph nodes and fibrous 
connective tissue.  Tissues were finely minced using sterile scissors to form a 
slurry that was subsequently digested with 0.1% collagenase type II (Sigma-
Aldrich, USA) in high glucose DMEM at 37°C with shaking at 200 rpm for 60-90 
min at a 45° angle.  Digested tissues were filtered through a 70 µm nylon mesh.  
The mesh was washed with approximately 20 mL Wash Media (high glucose 
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DMEM supplemented with 5% heat-inactivated fetal bovine serum [FBS], 100 
units/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine).  All Wash 
Media reagents were from Life Technologies (Grand Island, NY) except FBS, 
which was from Denville Scientific (South Plainfield, NJ).  Washed cells were 
centrifuged at 500 x g for 5 min at 4°C, and then floating adipocytes were 
removed by aspiration and the stromal vascular fraction (SVF) pellet was 
resuspended in red blood cell lysis buffer (ACK RBC Lysis Buffer) and allowed to 
incubate at room temperature for 2 min.  The RBC Lysis reaction was stopped by 
addition of 10 volumes Wash Media, and the SVF cells were recovered by 
centrifugation at 500 x g for 5 min at 4°C.  Cells were resuspended in 200 µL 
Wash Media and aliquotted in equal parts for immediate flow cytometric analysis 
or for re-stimulation as described below for subsequent intracellular cytokine 
analysis by flow cytometry.  In some experiments, all recovered SVF cells were 
used for immediate flow cytometric analyses. 
 
2.3.8  Surface and nuclear staining of murine cells for flow cytometric 
analyses   
Isolated SVF cells from mice were resuspended in 100 µL FACS PBS (sterile 1X 
phosphate buffered saline [Invitrogen] supplemented with 2% heat-inactivated 
FBS and 1 mM EDTA [Invitrogen]) containing LIVE/DEAD Fixable Aqua Dead 
Cell Stain (1:600) and anti-mouse IL-33R-biotin (T1/S2, clone DJ8) from MD 
Bioproducts (St. Paul, MN) (1:300).  Cells were incubated on ice for 30 min in the 
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dark and were washed twice in 250 µL FACS PBS with centrifugation at 500 x g 
for 5 min at 4°C before each wash.  Washed cells were stained with 
combinations of the following antibodies (all of which were used at 1:300 dilutions 
unless otherwise noted) in a volume of 90 µL staining buffer (FACS PBS 
supplemented with 20 µg/mL rat IgG): anti-mouse CD45-eFluor 605NC (clone 
30-F11; 1:200), CD45.1-eFluor 450 (A20; 1:100), CD45.2-AlexaFluor 700 (104), 
F4/80-eFluor 450 (BM8), CD3e-PerCP-Cy5.5 (145-2C11), CD5-PerCP-Cy5.5 
(53-7.3), CD19-PerCP-Cy5.5 (1D3), NK1.1-PerCP-Cy5.5 (PK136), CD11c-
PerCP-Cy5.5 (N418), FcεRIα-FITC (MAR-1), Foxp3-FITC (FJK-16s; 1:100), 
GATA-3-PE (TWAJ; 1:100) and CD25-PE-Cy7 (clone PC61.5) from eBioscience 
(San Diego, CA); CD11b-PE-Texas Red (M1/70.15; 1:500) from Life 
Technologies (Grand Island, NY); CD90.2-Alexa Fluor 700 (30-H12; 1:400) and 
CD4-Brilliant Violet-650 (RM4-5) from BioLegend (San Diego, CA); SiglecF-PE 
(E50-2440) and CD3e-PE-CF594 (145-2C11) from BD Biosciences (San Jose, 
CA); CD206-Alexa Fluor 647 (MR5D3; 1:200) from AbD Serotec (Raleigh, NC); 
and Streptavidin-APC (1:300) from eBioscience. Foxp3, GATA-3 and CD206 
staining was performed following fixation and permeabilization with the Foxp3 
Staining Buffer Set (eBioscience) according to the manufacturer’s protocol.  All 
intracellular stains were performed in 1X Permeabilization Buffer (PB, 
eBioscience) for 45 min on ice.  Cells were washed 3 times in 250 µL 1X PB with 
centrifugation at 500 x g for 5 minutes at 4 °C between washes, and recovered 
cells were resuspended in 200 µL FACS Buffer before flow cytometric analyses. 
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2.3.9  Surface and nuclear staining of human cells for flow cytometric 
analyses 
Isolated SVF cells from human tissues were resuspended in 100 µL FACS PBS 
(sterile 1X phosphate buffered saline [Invitrogen] supplemented with 2% heat-
inactivated FBS and 1 mM EDTA [Invitrogen]) containing LIVE/DEAD Fixable 
Aqua Dead Cell Stain (1:600) and anti-human FcεRIα-biotin (AER-37; 
eBioscience; 1:100).  Cells were incubated on ice for 30 min in the dark and were 
washed twice in 250 µL FACS PBS with centrifugation at 500 x g for 5 min at 4°C 
before each wash.  Washed cells were stained with combinations of the following 
antibodies in a volume of 90 µL FACS PBS (all of which were used at 1:100 
dilutions unless otherwise noted): anti-human GATA-3-PE (TWAJ), TCRαβ-
PerCP-Cy5.5 (IP26), CD5-PerCP-Cyanin5.5 (L17F12), CD19-Alexa Fluor 700 
(HIB19), CD11c-Alexa Fluor 700 (3.9), CD127-eFluor 780 (eBioRDR5; 1:50), 
CD45-eFluor 605NC (HI30; 1:50), FcεRIα-biotin (AER-37) and Streptavidin-
eFluor 650NC from eBioscience; CD56-Alexa Fluor 700 (B159), CD16-Alexa 
Fluor 700 (3G8), CD3 (SP34-2) and CD25-PE-Cy7 (M-A251; 1:50) from BD 
Pharmingen; CD11b-PE-Texas Red (M1/70.15; 1:300) from Life Technologies; 
and ST2L-FITC (B4E6; 1:50) from MD Bioproducts. GATA-3 and CD3 staining 
was performed following fixation and permeabilization with the Foxp3 Staining 
Buffer Set (eBioscience) according to the manufacturer’s protocol.  All 
intracellular stains were performed in 1X Permeabilization Buffer (PB, 
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eBioscience) for 45 min on ice.  Cells were washed 3 times in 250 µL 1X PB with 
centrifugation at 500 x g for 5 minutes at 4 °C between washes, and recovered 
cells were resuspended in 200 µL FACS Buffer before flow cytometric analyses. 
 
2.3.10  Intracellular cytokine analysis 
To examine ILC2 effector cytokine production, single cell suspensions of E-WAT 
or iWAT SVF were stimulated for 4 hours ex vivo with Phorbol 12-myristate 13-
acetate (PMA) (100 ng/mL) and ionomycin (1 ng/mL) in the presence of Brefeldin 
A (10 µg/mL) (all from Sigma-Aldrich) in a 37°C incubator (5% CO2).  Cells were 
then surface stained and fixed/permeabilized using Cyto Fix/Perm (BD 
Pharmingen) according to manufacturer’s instructions before intracellular staining 
for IL-5 (APC-IL-5, clone TRFK5, 1:200, eBioscience) and IL-13 (PE-IL-13, 
eBio13A, 1:200, eBioscience).  All intracellular stains were performed in 90 µL 1X 
Permeabilization Buffer (PB, eBioscience) for 45 min on ice.  After each 
intracellular stain, cells were washed 3 times in 250 µL 1X PB with centrifugation 
at 500 x g for 5 minutes at 4°C between washes. Recovered cells after the final 
wash were resuspended in 200 µL FACS Buffer before flow cytometric analyses. 
 
2.3.11  Flow cytometry 
For all flow cytometry analyses, stained cells were acquired on a BD LSRII flow 
cytometer (BD Biosciences).  The entirety of each sample was acquired to obtain 
total cell counts, which were subsequently normalized to tissue weight.  Flow 
 
 
47 
cytometry data were analyzed using FlowJo software version 9.6.4 (Tree Star, 
Inc.). 
 
2.3.12  Statistical analyses 
Data are expressed as mean ± standard error of the mean (SEM).  Statistical 
significance was determined for Normally-distributed data by using the two-tailed 
Student’s t test or a one-way or two-way analysis of variance (ANOVA) followed 
by Sidak or Tukey post-hoc tests.  If variance differed between groups, the 
appropriate statistical correction was applies (e.g. Welch’s correction). 
Correlation analyses were conducted using Pearson linear regression. 
Proportions among human samples were compared by Chi-squared tests. 
Significance was set at P<0.05.  Statistical analyses were performed with Prism 6 
(GraphPad Software, Inc.) or SPSS Statistics version 22 (IBM). 
 
2.4 Results 
2.4.1  Identification of ILC2s in human and murine white adipose tissue 
To address whether ILC2s are present in human and murine WAT, we first 
obtained abdominal subcutaneous white adipose tissues (WAT) from non-obese 
human donors and identified a lineage (Lin)-negative cell population that 
expresses CD25 (IL-2Rα) and CD127 (IL-7Rα) (Fig. 5a,b).  This cell population 
was positive for GATA binding protein 3 (GATA-3) and the IL-33 receptor (IL-
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33R) (Fig. 5c), a phenotype that is consistent with ILC2s identified in other 
human tissues (Kim et al., 2013; Mjosberg et al., 2012; Mjosberg et al., 2011; 
Monticelli et al., 2011).  A Lin− CD25+ CD127+ cell population (Fig. 6a) that 
expresses CD90, GATA-3 and IL-33R but not CCR6 (Fig. 6b) was also identified 
in epididymal WAT (E-WAT) of mice, similar to murine ILC2s described 
previously (Furusawa et al., 2013; Molofsky et al., 2013; Monticelli et al., 2011; 
Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al., 2013).  In 
mice, Lin− CD25+ CD127+ cells in E-WAT were developmentally dependent on 
Id2, TCF-7 and γc (Fig. 7a-c), indicating that these cells exhibit a developmental 
profile similar to ILC2s described in other murine tissues (Monticelli et al., 2011; 
Moro et al., 2010; Neill et al., 2010; Yang et al., 2013a).  In addition, Lin− CD25+ 
CD127+ cells from murine E-WAT produced the type 2 effector cytokines IL-5 
and IL-13 (Fig. 7d).  Collectively, these data identify ILC2s in human and murine 
WAT and indicate that murine E-WAT ILC2s exhibit phenotypic, developmental 
and functional similarities to ILC2s found in other mammalian tissues. 
 
2.4.2  Obesity is associated with decreased ILC2 populations in white 
adipose tissue in both mice and humans 
To examine whether human ILC2 responses are dysregulated in the setting of 
obesity, we compared ILC2 frequencies in abdominal subcutaneous WAT from 
non-obese versus obese donors (Table 1).  Donors were categorized as non-
obese (n=7) if their body mass index (BMI) was less than 30.0 kg/m2 or as obese 
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if their BMI was greater than or equal to 30.0 kg/m2 (n=7), a standardized 
threshold for defining an individual as clinically obese (Flegal et al., 2014). 
Strikingly, WAT from obese donors exhibited significantly decreased frequencies 
of ILC2s compared to non-obese controls (Fig. 8a,b).  In linear regression 
analyses ILC2 frequencies in WAT were also inversely correlated with BMI (Fig. 
8c).  These findings suggest that ILC2s in WAT are decreased human obesity 
compared to the non-obese state.   
 
To examine the association between human ILC2 frequencies in WAT and 
obesity, potential confounding variables including source of tissue, age, sex and 
some co-morbidities were analyzed to determine whether these factors might 
explain observed differences in ILC2 frequencies (Table 1).  As tissues were 
obtained from the New York Organ Donor Network (NYODN) and the 
Cooperative Human Tissue Network-Eastern Division (CHTN), the source of 
tissue was assessed.  The obese donors from each source tended to have lower 
WAT ILC2 frequencies compared to non-obese donors from the same source 
(Fig. 9a).  Although WAT ILC2 frequencies in obese donors tended to be lower in 
obese donors from CHTN vs NYODN (Fig. 9a), this difference appeared to be 
explained by higher BMI values in the obese group from CHTN (Fig. 9b). 
 
In addition, analyses showed that the obese donors were significantly older than 
the non-obese donors (Table 1, P=0.042). Therefore, we performed additional 
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analyses comparing WAT ILC2 frequencies between the younger 50%ile (n=7, 
36.0 +/- 3.5 years) and the older 50%ile (n=7, 55.9 +/- 1.9 years).  WAT ILC2 
frequencies did not differ according to age groups (P=0.71, Fig. 10a), indicating 
that age does not explain differences observed in WAT ILC frequencies between 
non-obese and obese donors.  In addition, the obese donors were predominantly 
females (6 of 7 donors) in contrast to the non-obese donors (3 of 7 donors) 
(Table 1, P=0.094).  This distribution of biological sex precluded comparisons of 
ILC2 frequencies in males vs females, and analyzes comparing non-obese 
versus obese WAT ILC2 frequencies in only males were not possible due to 
small sample sizes in the obese group.  However, when analyses were restricted 
to females only, WAT ILC2 frequencies remained significantly decreased in 
obese vs non-obese donors (Fig. 10b).  These results suggest that biological sex 
also does not explain differences observed in WAT ILC frequencies between 
non-obese and obese donors.  The non-obese and obese donors did not differ 
significantly for history of type 2 diabetes, liver disease or cardiovascular disease 
(Table 1), suggesting that these co-morbidities also do not explain differences 
observed in WAT ILC2 frequencies between non-obese and obese donors. 
 
Next, to test whether ILC2s in WAT are also dysregulated in murine obesity, mice 
were fed a control diet (CD) or high fat diet (HFD). HFD feeding was associated 
decreased frequencies and numbers of ILC2s in E-WAT of HFD-fed mice 
compared to CD-fed controls (Fig. 11a,b).  These data indicate that ILC2s are 
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also decreased in WAT of diet-induced obese mice and suggest that decreased 
ILC2 populations are a conserved characteristic of obesity in mice and humans.  
 
2.4.3  Endogenous IL-33 sustains ILC2 responses in WAT and limits the 
development of spontaneous obesity 
Previous studies demonstrated that IL-33 promotes ILC2 responses in WAT and 
other murine tissues in inflammatory settings (Furusawa et al., 2013; Imai et al., 
2013; Molofsky et al., 2013; Monticelli et al., 2011; Moro et al., 2010; Neill et al., 
2010; Saenz et al., 2013), however it is unclear whether IL-33 regulates basal 
ILC2 responses.  We therefore employed IL-33-deficient mice to test whether 
endogenous IL-33 regulates ILC2 responses. Strikingly, Il33−/− mice exhibited 
decreased frequencies and numbers of ILC2s in E-WAT (Fig. 12a) and iWAT 
(Fig. 12b) compared to Il33+/+ controls at steady state.  Further, expression of IL-
5 and IL-13 by ILC2s from E-WAT or iWAT was decreased in Il33−/− mice 
compared to controls (Fig. 13).  These data indicate that endogenous IL-33 is 
required to maintain normal ILC2 frequencies and numbers and functional 
potential in WAT. 
 
As ILC2s have previously been implicated in limiting weight gain in the context of 
HFD feeding and in enhancing glucose homeostasis (Hams et al, 2013), we next 
sought to test whether IL-33-deficient mice exhibited abnormal metabolic 
homeostasis under basal conditions.  Male IL-33-deficient or -sufficient mice 
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were fed a CD (10% kcal fat) starting at 7 weeks of age for a period of 12 weeks. 
Strikingly, over the first 10 weeks of the feeding regimen, mice lacking IL-33 
gained more weight than controls in terms of absolute and relative mass (Fig. 
14a,b).  This was associated with increased E-WAT and iWAT accumulation (Fig. 
14c), increased white adipocyte size (Fig. 14d) and higher whole body adiposity 
(Fig. 14e) in IL-33-deficient mice compared controls.  In addition, Il33−/− mice 
exhibited impaired glucose homeostasis as evidenced by fasting euglycemic 
hyperinsulinemia (Fig. 15a,b), increased homeostatic model assessment of 
insulin resistance (HOMA-IR) index values (Fig. 15c), impaired glucose tolerance 
(Fig. 15d) and impaired insulin tolerance (Fig. 15e). Together, these results 
indicate that endogenous IL-33 is required to maintain normal ILC2 responses in 
WAT and to limit the development of spontaneous obesity.  
 
2.4.4  Recombinant IL-33 treatment elicits ILC2 responses in white adipose 
tissue and decreases adiposity 
We next employed a complementary gain-of-function approach to examine 
whether IL-33 treatment could elicit ILC2 responses in WAT of HFD-fed mice and 
limit the development of obesity.  Mice were fed a CD or HFD for 4 weeks, and 
HFD-fed mice were treated with PBS or rmIL-33 once every 4 days starting on 
the first day of the feeding regimen.  At this early time point (4 weeks), HFD-fed 
mice treated with PBS exhibited decreased ILC2 numbers in E-WAT compared 
to controls (Fig. 16a), a result that is similar to longer HFD feeding regimens (Fig 
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11b).  Further, rmIL-33 treatment was associated with markedly increased ILC2 
numbers in E-WAT (Fig. 16a), indicating that rmIL-33 treatment produced a 
robust ILC2 response in the setting of HFD feeding.  Strikingly, HFD mice treated 
with rmIL-33 exhibited decreased body weight (Fig. 16b) and lower accumulation 
of E-WAT and iWAT mass (Fig. 16c,d) compared to HFD mice treated with PBS.  
These changes were associated with improved fasting blood glucose levels (Fig. 
16e) and enhanced glucose tolerance (Fig. 16f).  Collectively, these data indicate 
that exogenous IL-33 can promote ILC2 responses and ameliorate HFD-induced 
obesity in association with improved glucose tolerance. 
 
We next tested whether rmIL-33 treatment for 7 days could decrease adiposity in 
lean mice.  As expected, rmIL-33 treatment resulted in increased frequencies 
and numbers of ILC2s in E-WAT (Fig. 17a) and iWAT (Fig. 17b).  Although body 
weight did not differ between groups (Fig. 17c), mice treated with rmIL-33 had 
significantly decreased whole body adiposity compared to controls (Fig. 17d), 
indicating that exogenous rmIL-33 can decrease fat mass in lean mice. 
 
2.4.5  Recombinant IL-33 treatment increases caloric expenditure of mice 
To examine the mechanisms by which IL-33 regulates adiposity, we assessed 
energy homeostasis in lean mice treated with PBS or rmIL-33 daily for 7 day and 
employed Comprehensive Laboratory Animal Monitoring System (CLAMS) cages 
to simultaneously assess caloric expenditure and intake during days 6-to-7 over 
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a 24 hour period.  rmIL-33 treatment resulted in a significantly increased caloric 
expenditure compared to controls (Fig. 17e).  However, rmIL-33 treatment did not 
result in altered food intake (Fig. 18a). The absence of hyperphagia in the setting 
of increased caloric expenditure, as observed in this experimental system, 
appeared to be related to decreased ambulatory activity levels. Supporting this, 
mice treated with rmIL-33 exhibited decreased ambulatory activity compared to 
controls (Fig. 18b). In addition, decreases in ambulatory activity over 15 min 
intervals in rmIL-33- vs PBS-treated mice were significantly correlated with 
decreased food intake over the same time intervals in rmIL-33- vs PBS-treated 
mice (Fig. 18c).  Taken together, these data suggest that increased caloric 
expenditure in rmIL-33-treated mice could not be explained by the thermic effect 
of food or physical activity levels but was regulated by other physiologic 
processes. 
 
2.5 Discussion 
Data presented in this Chapter identify IL-33R+ ILC2s in human and murine WAT 
and demonstrate that decreased ILC2 populations in WAT is a conserved 
characteristic of obesity in both humans and mice.  Furthermore, this Chapter 
demonstrates that IL-33 is critical for regulating ILC2 responses in WAT and for 
limiting obesity in mice.  Mice lacking IL-33 had impaired ILC2 responses and 
developed spontaneous obesity on a low fat diet. Further, treatment of HFD-fed 
wildtype mice with recombinant murine IL-33 increased ILC2 accumulation in 
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WAT and ameliorated the development of obesity.  IL-33-mediated decreases in 
adiposity were associated with increased caloric expenditure. 
 
Previous studies demonstrated that ILC2s in WAT are decreased in mice fed a 
HFD compared to lean controls (Molofsky et al., 2013) and that transfer of IL-25-
elicited ILC2s could decrease body weight and improve insulin sensitivity in HFD-
fed mice (Hams et al., 2013).  ILC2s are known to produce the effector cytokines 
IL-5 and IL-13 to promote eosinophil and AAMac responses, respectively, in 
WAT (Molofsky et al., 2013), and both eosinophils and AAMacs are reported to 
limit obesity (Chang et al., 2012; Odegaard et al., 2007; Odegaard et al., 2008; 
Ricardo-Gonzalez et al., 2010; Wu et al., 2011).  These studies provoke the 
hypothesis that the function of ILC2s in WAT is to sustain eosinophils and 
AAMacs to maintain optimal metabolic homeostasis.  Consistent with this, 
treatment of mice with exogenous IL-33 is associated with increased ILC2, 
eosinophil and AAMac frequencies and numbers in WAT and attenuated weight 
gain in genetically obese ob/ob mice (Miller et al., 2010; Molofsky et al., 2013).  
Further, IL-33R-deficient mice are reported to be more susceptible to diet-
induced obesity compared to IL-33R-sufficient controls (Miller et al., 2010).  
However, ILC2s have not been previously identified in human WAT, and the 
endogenous factors that regulate ILC2s in WAT remain poorly characterized.  In 
this Chapter, we identify a lineage-negative CD25+ CD127+ GATA-3+ IL-33R+ cell 
population in human WAT consistent with ILC2s identified in other human tissues 
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(Bartemes et al., 2014; Hams et al., 2014; Kim et al., 2013; Kim et al., 2014; 
Mjosberg et al., 2012; Mjosberg et al., 2011; Monticelli et al., 2011; Spits et al., 
2013; Xue et al., 2014), and demonstrate that obesity in both humans and mice 
is associated with decreased ILC2 populations in WAT.  Through loss-of-function 
studies we also identify that IL-33 is necessary to maintain ILC2 responses and 
limit the development of obesity.  Collectively, these results indicate that the IL-
33/ILC2 axis is operational in the steady state to limit adiposity and suggest that 
decreases in ILC2s in WAT in the context of obesity might be one factor that 
contributes to weight gain. 
 
IL-33 is highly expressed in white adipose tissue (Thorrez et al., 2008) and is 
produced predominantly by adipocytes and endothelial cells (Zeyda et al., 2013).  
Expression levels of IL-33 mRNA and protein are reported to be increased in 
WAT of obese humans compared to non-obese controls and in HFD-fed mice 
compared to LFD-mice (Zeyda et al., 2013).  In serum, however, IL-33 levels in 
sera of humans and mice appear to be unchanged (Zeyda et al., 2013) or 
decreased (Hasan et al., 2014) in the context of obesity, suggesting that there 
may be tissue-specific effects of obesity on IL-33 levels.  Although increased IL-
33 levels in WAT would be expected to elicit WAT ILC2 responses, our 
observation that ILC2s are decreased in obesity suggests that perhaps the IL-
33/ILC2 axis might be dysregulated in established obesity.  Future studies to 
address this topic are warranted. 
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The data in this Chapter also indicate that administration of exogenous IL-33 can 
elicit ILC2 responses in association with decreased adiposity and enhanced 
glucose tolerance. These beneficial metabolic effects of the IL-33/ILC2 pathway 
are consistent with previous studies showing a protective role for IL-33 in 
genetically obese mice and may be related to obesity-associated pathologies 
such as atherosclerosis that are limited by IL-33 (Hasan et al., 2014; Miller et al., 
2010; Miller et al., 2008).  However, whether IL-33 has protective effects against 
obesity through regulation of caloric expenditure or intake remains poorly 
characterized.  In this Chapter, we demonstrate that chronic IL-33 treatment is 
associated with increased caloric expenditure but not decreased food intake.  
Although increased metabolic rate would be expected to result in compensatory 
increases in food intake to maintain energy balance, IL-33 did not have this 
effect, apparently due to decreased activity levels and possibly other processes.  
Importantly, these data suggest that IL-33 does not increase caloric expenditure 
via the thermic effect of food or through increased activity levels, two important 
factors that influence metabolic rate (Poehlman and Horton, 1989), and suggest 
that other physiologic processes are responsible for the increased energy 
expenditure following IL-33 treatment.  
 
At steady state WAT contains a diverse set of type 2 cytokine-associated 
immune cells that are critical for the maintenance of metabolic homeostasis 
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(Gregor and Hotamisligil, 2011; Jin et al., 2013; Lumeng and Saltiel, 2011; 
Odegaard and Chawla, 2011; Osborn and Olefsky, 2012). Emerging studies 
suggest that ILC2s are a critical upstream mediator of the eosinophil/IL-4/AAMac 
pathway in WAT that has been previously demonstrated to maintain metabolic 
homeostasis and limit the development of obesity (Chang et al., 2012; Hams et 
al., 2013; Molofsky et al., 2013; Odegaard et al., 2007; Qiu et al., 2014; Ricardo-
Gonzalez et al., 2010; Wu et al., 2011; Xu et al., 2013).  The data in this Chapter 
indicate that decreased ILC2s in WAT is a conserved feature of obesity in mice 
and humans.  In addition, we demonstrate that IL-33 is necessary and sufficient 
to promote ILC2 responses in WAT and limit the development of obesity.   As 
adipocytes are an important source of IL-33 in the context of increased weight 
gain (Zeyda et al., 2013), the IL-33/ILC2 axis may represent one mechanism for 
mammals to couple metabolic changes in adipose to innate immune pathways 
that increase caloric expenditure.  Dysregulation of the IL-33/ILC2 pathway may 
therefore promote increases in adiposity.  In addition, these findings suggest that 
the IL-33/ILC2 axis might be a useful therapeutic target to treat obesity. 
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2.6  Tables and Figures 
 
Table 1.  Characteristics of non-obese and obese human donors.  
Characteristic 
Non-obese 
(n=7) 
Obese 
(n=7) 
P-value* 
Source of tissue  
(% CHTN/% NYODP) 
29/71 43/57 P=0.43 
Age 39.3 +/- 5.2 52.6 +/- 2.7 P=0.042 
Sex, % female 43 87 P=0.094 
BMI (kg/m2) 23.5 +/- 1.4 42.6 +/- 3.9 P=0.0006 
History of Type 2 diabetes (%) 14 43 P=0.24 
History of liver disease (%) 0 0 n/a 
History of cardiovascular disease (%) 0 13 P=0.30 
 
BMI, body mass index; CHTN, Cooperative Human Tissue Network; NYODP, 
New York Organ Donor Program 
*Proportions were compared by X2 tests. Continuous variables were compared 
by Student’s t-test. Exact P-values are shown. 
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Figure 5.  Identification of human Group 2 innate lymphoid cell (ILC2s) 
in white adipose tissue (WAT).  (a) Gating strategy to identify human 
ILCs.  Stromal vascular fraction (SVF) cells from human abdominal 
subcutaneous WAT were isolated and subjected to flow cytometric 
analyses. First plot pre-gated on singlets.  Lineage cocktail 1 (Lin1): CD3, 
CD5, TCRαβ. Lineage cocktail 2 (Lin2): CD19, CD56, CD11c, CD16. ILCs 
are identified as Lin-negative cells that are CD25+ CD127+. Plots shown are 
from an obese donor. (b) Identification of lineage (Lin)-negative CD25+ 
CD127+ innate lymphoid cells (ILCs) in human abdominal subcutaneous 
WAT from a lean donor.  Pre-gated on live CD45+ Lin− cells that lack CD3, 
CD5, TCRαβ, CD19, CD56, CD11c, CD11b, CD16, and FcεRIα.  (c) 
Histograms of GATA-3 and IL-33R expression by human WAT ILCs (line).  
Shaded histogram, isotype control.  Gated on live CD45+ Lin− CD25+ 
CD127+ ILCs. 
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Figure 6.  Identification of murine Group 2 innate lymphoid cell 
(ILC2s) in white adipose tissue (WAT).   (a) Gating strategy to identify 
murine ILCs.  Stromal vascular fraction (SVF) cells from murine epididymal 
(E)-WAT were isolated and subjected to flow cytometric analyses. First 
plot pre-gated on singlet live cells.  Lineage cocktail 1 (Lin1): CD3, CD5, 
CD19, NK1.1. Lineage cocktail 2 (Lin2): CD19, CD11c. ILCs are identified 
as Lin-negative cells that are CD25+ CD127+. (b) Phenotypic 
characterization of ILCs from murine E-WAT.  Left-hand plot shows 
Identification of Lin− CD25+ CD127+ ILCs in murine epididymal (E)-WAT.  
Pre-gated on live CD45+ Lin− cells that lack CD3, CD5, CD19, NK1.1, 
CD11c, CD11b and FcεRIα.  Right-hand plots are gated on live CD45+ Lin− 
CD25+ CD127+ ILCs and show histograms of CD90, CCR6, GATA-3 and 
IL-33R expression by murine E-WAT ILCs (line).  Shaded histogram, 
isotype control. 
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Figure 7.  Developmental and functional characteristics of murine 
ILCs from epididymal white adipose tissue (E-WAT).  (a-c) Stromal 
vascular fraction (SVF) cells from murine E-WAT were isolated and 
subjected to flow cytometric analyses.  ILCs were defined as live CD45+ 
Lin− CD25+ CD127+ cells. The lineage (Lin) cocktail included CD3, CD5, 
CD19, NK1.1, CD11c, CD11b and FcεRIα.  Comparison of Lin− CD25+ 
CD127+ cells in E-WAT of (a) Id2+/+ versus Id2−/− bone marrow chimeras, 
(b) Tcf7+/+ versus Tcf7−/− mice and (c) Rag2−/−  versus Rag2−/− γc−/− mice.  
N=3-8 mice per group from 2 independent experiments.  (d) E-WAT SVF 
cells from C57BL/6 mice were treated with PMA (100 ng/mL) and 
ionomycin (1 µg/mL) in the presence of Brefeldin A (10 µg/mL) for 4h and 
stained for ILCs.  Live CD45+ Lin- CD25+ CD127+ IL-33R+ cells were pre-
gated, and IL-5 and IL-13 protein levels were assessed. Plot shown is 
representative of n=12 mice from 3 independent experiments. 
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Figure 8.  ILC2 populations in human white adipose tissue (WAT) are 
decreased in obese patients.  (a) Representative plots and (b) frequencies 
of human WAT ILC2s from donors stratified into non-obese (body mass 
index [BMI]<30.0 kg/m2, n=7) and obese (BMI≥30.0 kg/m2, n=7) groups.  
Pre-gated on live CD45+ Lin− cells that lack CD3, CD5, TCRαβ, CD19, 
CD56, CD11c, CD11b, CD16, and FcεRIα. Student’s t-test, *P<0.05.  (c) 
Frequencies of ILC2s are inversely correlated with BMI.  Vertical dashed line 
demarcates BMI = 30.0 kg/m2.  Linear regression.  Pearson correlation 
moment (r) is of the best-fit line, which is shown on the graph.  Exact P-value 
shown. *P<0.05. 
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Figure 9.  ILC2 frequencies tend to be decreased in human white 
adipose tissue (WAT) irrespective of source, and differences in ILC2 
frequencies between sources are explained by body mass index 
(BMI).  (a) Frequencies of human ILC2s (Lin− CD25+ IL-33R+ cells) in 
subcutaneous WAT of non-obese (BMI < 30.0 kg/m2) and obese (BMI ≥ 
30.0 kg/m2) donors stratified by source of tissue.  Gated on live CD45+ 
Lin− CD25+ IL-33R+ cells.  The lineage (Lin) cocktail included CD3, CD5, 
TCRαβ, CD19, CD56, CD11c, CD11b, CD16, and FcεRIα. NYODN, New 
York Organ Donor Network. CHTN, Cooperative Human Tissue Network-
Eastern Division. (b) BMI of non-obese and obese donors stratified by 
source of tissue. The horizontal dashed line demarcates the cut off of 
non-obese vs obese donors. Non-obese from NYODN, n=4. Non-obese 
from CHTN, n=3. Obese from NYODN, n=4. Obese from CHTN, n=3. 
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Figure 10.  Age and biological sex do not explain differences in WAT 
ILC2 frequencies observed between non-obese and obese donors.  (a) 
Human WAT ILC2 frequencies were compared in the 7 youngest donors (36.0 
+/- 3.5 years old) versus the 7 oldest donors (55.9 +/- 1.9 years old).  (b) 
Human WAT ILC2 frequencies in female non-obese donors with body mass 
index (BMI) <30.0 kg/m2 versus female obese donors with BMI ≥30.0 kg/m2. 
In both panels, ILC2s were defined as live CD45+ Lin− CD25+ IL-33R+ cells, 
where the lineage (Lin) cocktail included CD3, CD5, TCRαβ, CD19, CD56, 
CD11c, CD11b, CD16, and FcεRIα.  Student’s t-test. **P<0.01, ***P<0.001. 
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Figure 11.  ILC2 populations are decreased in epididymal white 
adipose tissue (E-WAT) of high fat diet (HFD)-induced obese mice.  
(a) Representative plots and frequencies of murine E-WAT ILC2s from 
mice fed a control diet (CD, 10% kcal fat, n=5) or high fat diet (HFD, 45% 
kcal fat, n=4) for 12 weeks.  (h) Numbers of murine ILC2s/gram E-WAT in 
mice fed a CD (n=8) or HFD (n=6) for 12 weeks.  Student’s t-test, 
**P<0.01, ***P<0.001. 
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Figure 12.  IL-33-deficient mice exhibit decreased frequencies and 
numbers of ILC2s in white adipose tissue (WAT).  Il33+/+ (n=6) or Il33−/− 
(n=5) mice were fed a low fat diet (10% kcal fat) for 12 weeks starting at 7 
weeks of age.  (a) Frequencies and numbers of live CD45+ Lin− CD25+ IL-
33R+ ILC2s in epididymal (E)-WAT.  Plots pre-gated on CD45+ Lin− cells 
that lack CD3, CD5, CD19, NK1.1, CD11c, CD11b and FcεRIα.  (b) 
Frequencies and numbers of live CD45+ Lin− CD25+ IL-33R+ ILC2s in 
inguinal (i)WAT.  Plots pre-gated on CD45+ Lin− cells that lack CD3, CD5, 
CD19, NK1.1, CD11c, CD11b and FcεRIα.  Student’s t-test, *P<0.05, 
**P<0.01. 
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Figure 13.  IL-33-deficient mice exhibit decreased frequencies and 
numbers of ILC2s in white adipose tissue (WAT).  Il33+/+ (n=6) or 
Il33−/− (n=5) mice were fed a low fat diet (10% kcal fat) for 12 weeks 
starting at 7 weeks of age.  Epididymal (E)-WAT and inguinal (i)WAT 
SVF were treated with PMA (100 ng/mL) and ionomycin (1 µg/mL) in the 
presence of Brefeldin A (10 µg/mL) for 4h prior to staining for ILC2s and 
intracellular cytokines.  Representative plots and frequencies of IL-5+ IL-
13− and IL-5+ IL-13+ ILC2s from E-WAT and iWAT are shown.  Plots pre-
gated on CD45+ Lin− CD25+ IL-33R+ ILC2s, where the lineage (Lin) 
cocktail included CD3, CD5, CD19, NK1.1, CD11c, CD11b and FcεRIα.  
Student’s t-test, ***P<0.001. 
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Figure 14.  IL-33-deficient mice gain more weight and exhibit 
increased adiposity compared to IL-33-sufficient mice.  Il33+/+ (n=6) or 
Il33−/− (n=5) mice were fed a low fat diet (10% kcal fat) for 12 weeks 
starting at 7 weeks of age.  (a) Absolute and (b) relative body weights over 
the first 10 weeks of feeding.  (c) Absolute and relative epididymal (E)-
WAT and inguinal (i)WAT weights.  (d) iWAT sections were H&E stained 
and imaged at 40X magnification. Adipocyte area was calculated from 25-
40 adipocytes total from 2-3 images per mouse.  (e) Body composition 
analyses.  Student’s t-test or ANOVA with repeated measures.  *P<0.05, 
**P<0.01, ***P<0.001. 
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Figure 15.  IL-33-deficient mice exhibit impaired glucose homeostasis. 
Il33+/+ (n=6) or Il33−/− (n=5) mice were fed a low fat diet (10% kcal fat) for 12 
weeks starting at 7 weeks of age.  On week 10, mice were fasted for 16 hours 
followed by glucose tolerance testing (GTT). On week 11, mice were fasted 
for 4-6 hours followed by insulin tolerance testing (ITT).  (a) 16-hour fasting 
blood glucose concentrations.  (b) 16-hour fasting serum insulin 
concentrations.  (c) Homeostatic model assessment of insulin resistance 
(HOMA-IR) index values.  (d)  GTT with 2 g/kg glucose following a 16-hour 
fast.  (e) ITT with 0.5 U/kg insulin following a 5-hour fast. For panels a-c, 
groups were compared using Student’s t-test, *P<0.05.  For panels d-e, a 
two-way ANOVA with repeated measures was performed followed by Tukey 
post-hoc test. *P<0.05, **P<0.01, ***P<0.001. Data shown are from a single 
cohort and are representative of 2 independent experiments. 
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Figure 16.  IL-33 increases E-WAT ILC2s and abrogates the development 
of obesity and glucose intolerance in mice fed a high fat diet (HFD).  Male 
C57BL/6 mice were placed on a control diet (CD) or HFD (60% kcal fat) at age 
8 weeks.  On the first day of feeding, CD mice were treated with PBS and HFD 
mice were treated with PBS or recombinant murine (rm)IL-33 (12.5 µg/kg) once 
every 4 days by intraperitoneal injection for 4 weeks.  (a)  E-WAT ILC2 numbers 
per gram of adipose, (b) body weight, (c) relative E-WAT weight and (d) relative 
iWAT weight at week 4.  (e) 16-hour fasting blood glucose concentrations and 
(f) glucose tolerance testing during week 3.  All panels include n=10 mice per 
group from 2 independent cohorts, except panel A which includes n=16 CD 
PBS and n=18 HFD PBS from 4 independent cohorts.  Panels a-e, One-way 
ANOVA with Tukey post-hoc test,* P<0.05, **P<0.01, ***P<0.001.   Panel f, 
Two-way ANOVA with repeated measures, ***P<0.001 comparing CD PBS vs 
HFD PBS, ^^^P<0.001 comparing HFD PBS vs HFD IL-33.  
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Figure 17.  Exogenous IL-33 promotes ILC2 responses in white adipose 
tissue and limits adiposity in association with increased caloric 
expenditure.  Wildtype mice were treated with phosphate buffered saline 
(PBS, n=10) or recombinant murine IL-33 (12.5 µg/kg/day, n=12) by 
intraperitoneal injection for 7 days.  (a-b) Representative plots with 
frequencies and numbers of ILC2s in (a) epididymal (E)-WAT and (b) 
inguinal (i)WAT. (c) Body weight and (k) body composition.  (l) Caloric 
expenditure over a 24-hour period, days 6-to-7 of treatment.  Non-shaded 
area, lights on.  Shaded area, lights off.   
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Figure 18.  Exogenous IL-33 treatment does not affect food intake, and 
the absence of hyperphagia following IL-33 treatment may be due to 
decreased activity levels.  Wildtype mice were treated with phosphate 
buffered saline (PBS, n=10) or recombinant murine IL-33 (12.5 µg/kg/day, 
n=12) by intraperitoneal injection for 7 days.  (a) Food intake and (b) total 
activity levels (beam breaks) assessed by Comprehensive Laboratory Animal 
Monitoring System (CLAMS) cages over a 24 hour period between days 6 and 
7 of treatment.  Student’s t-test, *P<0.05.  (c) The average difference in food 
intake or ambulatory activity (beam breaks) between PBS- and rmIL-33-treated 
mice was calculated for each 15 min interval during the CLAMS cage analyses 
in panels a-b, and the differences in food intake and ambulatory activity at each 
time point were related by linear regression. Solid line, best-fit line.  Dashed 
curves, upper and lower 95% confidence intervals around the best-fit line.   
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Chapter 3:  The IL-33/ILC2 pathway promotes beiging of 
white adipose tissue 
 
 
 
3.1  Abstract 
Obesity is an increasingly prevalent disease regulated by genetic and 
environmental factors.  Emerging studies indicate that immune cells, including 
monocytes, granulocytes and lymphocytes, regulate metabolic homeostasis and 
are dysregulated in obesity.  Group 2 innate lymphoid cells (ILC2s) can regulate 
adaptive immunity and eosinophil and alternatively-activated macrophage 
responses, and were recently identified in murine white adipose tissue (WAT) 
where they may act to limit the development of obesity6.  In the previous Chapter, 
we demonstrated that decreased ILC2 populations in WAT are a conserved 
characteristic of obesity in humans and mice and that IL-33 is critical for 
maintaining ILC2s in WAT and limiting adiposity in mice by increasing caloric 
expenditure.  However the mechanisms by which IL-33 and ILC2s regulate 
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metabolic homeostasis remain unknown.  In this Chapter, we demonstrate that 
IL-33 treatment is associated with recruitment of uncoupling protein 1 (UCP1)+ 
beige adipocytes in WAT, a process known as beiging or browning that regulates 
caloric expenditure7-9.  IL-33-induced beiging appeared to be dependent on 
ILC2s, and IL-33 treatment or transfer of IL-33-elicited ILC2s was sufficient to 
drive beiging independently of the adaptive immune system, eosinophils or IL-4 
receptor signaling.  We found that ILC2s produce methionine-enkephalin 
peptides that can act directly on adipocytes to upregulate Ucp1 expression in 
vitro and that promote beiging in vivo.  Collectively, these studies indicate that in 
addition to responding to infection or tissue damage, ILC2s can regulate adipose 
function and metabolic homeostasis in part via production of enkephalin peptides 
that elicit beiging. 
 
3.2  Introduction 
Three adipocyte cell types – white, brown and beige – are regulated by gene-
environment interactions to differentially control energy storage and expenditure 
(Harms and Seale, 2013; Pfeifer and Hoffmann, 2014; Wu et al., 2013).  White 
adipocytes are found in white adipose tissues (WAT), store large amounts of 
triglycerides (TG) and produce a variety of hormones such as leptin, adiponectin, 
resistin and adipsin that regulate food intake and glucose homeostasis (Badoud 
et al., 2014; Peirce et al., 2014; Pfeifer and Hoffmann, 2014).  In contrast to white 
adipocytes, brown adipocytes are found in discrete brown adipose tissue (BAT) 
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depots, the largest of which is located in the interscapular space in mice, and 
contain multiple small lipid droplets and abundant Uncoupling protein 1 (UCP1)+ 
mitochondria that uncouple fatty acid and glucose oxidation from ATP synthesis, 
resulting in the production of heat (Cannon and Nedergaard, 2004; Harms and 
Seale, 2013).  This thermogenic process is dependent on UCP1 and is critical for 
defending core body temperature and regulating metabolic rate and the 
development of obesity(Carey et al., 2013; Cohen et al., 2014; Feldmann et al., 
2009; Harms and Seale, 2013; Rosen and Spiegelman, 2014; Saito et al., 2009; 
Wu et al., 2012; Wu et al., 2013; Yoneshiro et al., 2011).   
 
Recent studies have also identified a third adipocyte cell type, the beige 
adipocyte (also known as brite, brown-like or inducible brown adipocyte) that is 
dispersed within WAT but with morphologic and functional characteristics of 
brown adipocytes (Bartelt and Heeren, 2014; Harms and Seale, 2013; Wu et al., 
2013).  These specialized adipocytes emerge in WAT in response to 
environmental signals, a process known as beiging or browning, and also act to 
produce heat in an UCP1-dependent manner(Harms and Seale, 2013; Rosen 
and Spiegelman, 2014; Shabalina et al., 2013; Wu et al., 2012; Wu et al., 2013).  
UCP1 is highly expressed in brown and beige but not white adipocytes (Wu et 
al., 2012).  BAT in humans has been shown to contain adipocytes with 
morphologic and gene expression signatures consistent with beige rather than 
brown adipocytes (Jespersen et al., 2013; Sharp et al., 2012; Wu et al., 2012).  
 
 
77 
Activation of these beige/brown fat depots is defective in obese humans (Carey 
et al., 2013; Saito et al., 2009), and recent studies indicate that selective deletion 
of beige adipocytes while leaving BAT intact increases susceptibility to obesity in 
mice (Cohen et al., 2014).  Therefore beige adipocytes appear to be critical 
mediators of energy homeostasis. 
 
Although a variety of factors have been shown to activate both brown and beige 
adipocytes (Harms and Seale, 2013; Rosen and Spiegelman, 2014; Wu et al., 
2013), recent studies suggest that type 2 cytokine-associated immune cells such 
as eosinophils and alternatively activated macrophages (AAMacs) are necessary 
for optimal brown and beige adipocyte responses (Nguyen et al., 2011; Qiu et al., 
2014; Rao et al., 2014).  Mice that lack IL-4 and IL-13 (Il4/13−/−); the shared 
receptor for these cytokines, IL-4Rα (Il4ra−/−); or STAT6, a transcription 
downstream of IL-4Rα signaling (Stat6−/−) have defective AAMac responses 
(Martinez et al., 2009) and exhibit decreased upregulation of UCP1 expression in 
BAT and impaired defense of core body temperature following acute exposure to 
cold environmental temperatures (Nguyen et al., 2011).  IL-4 was shown to 
activate AAMacs to produce catecholamines such as norepinephrine (NE) that 
act on the β3 adrenergic receptor (β3AR) to stimulate lipolysis, elicit mitochondrial 
biogenesis and activate UCP1 in BAT (Nguyen et al., 2011).  However IL-4/IL-
4Rα interactions do not appear to be required for BAT responses in the context 
of chronic exposure to severe cold environmental temperatures over a period of 
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3 days (Qui et al., 2014).  In this context, eosinophils are recruited to WAT and 
produce IL-4 to stimulate AAMac production of NE to promote beiging of WAT 
(Qiu et al., 2014; Rao et al., 2014).  Mice lacking eosinophils, IL-4Rα or STAT6 
failed to undergo optimal beiging of WAT and had decreased metabolic rate 
compared to wildtype controls in the setting of chronic cold exposure (Qiu et al., 
2014; Rao et al., 2014).  Thus, the eosinophil/IL-4/AAMac/NE pathway appears 
to have a critical role in the elicitation of both brown and beige adipocyte 
responses and in the regulation of metabolic rate. 
 
Group 2 innate lymphoid cells (ILC2s) are a recently described innate immune 
cell that is a dominant source of IL-5 and IL-13 in WAT to promote eosinophil and 
AAMac responses, respectively (Molofsky et al., 2013; Moro et al., 2010; Neill et 
al., 2010; Nussbaum et al., 2013; Price et al., 2010).  ILC2s have been previously 
demonstrated to be decreased in WAT of obese mice (Molofsky et al., 2013) and 
limit the development of obesity (Hams et al., 2013).  However the mechanisms 
by which ILC2s regulate metabolic homeostasis in WAT remain poorly 
understood.  In the previous Chapter, we demonstrated that decreased ILC2s in 
WAT is a conserved characteristic of obesity in mice and humans, and that IL-33 
is critical for promoting ILC2 responses and decreasing adiposity by increasing 
caloric expenditure.  Collectively, these findings provoke the hypothesis that the 
IL-33/ILC2 axis might contribute to the regulation of caloric expenditure by 
promoting the activation of brown and/or beige adipocytes.   
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In this Chapter, we demonstrate that IL-33 treatment elicits beiging of WAT but 
does not stimulate expression of Ucp1 in BAT, suggesting that IL-33 has 
selective effects on beiging.  IL-33-induced beiging appeared to be dependent on 
ILC2s, and adoptive transfer of IL-33-elicited ILC2s was sufficient to drive beiging 
of WAT and to increase inguinal (i)WAT oxygen consumption.  Surprisingly, IL-33 
and ILC2 transfer could elicit beiging in the absence of eosinophils and IL-4Rα-
dependent AAMacs, suggesting that the IL-33/ILC2 axis can promote beiging via 
another mechanism.  Gene expression analyses of 69 genes previously linked to 
the development of obesity in humans revealed that ILC2s produce the 
neuropeptide methionine-enkephalin (MetEnk).  We show that MetEnk treatment 
is sufficient to drive beiging of WAT in vivo and can act directly on primary 
adipocytes from iWAT but not BAT to upregulate Ucp1 expression.  Collectively, 
these data indicate that the IL-33/ILC2 axis elicits beiging via production of 
MetEnk peptides. 
 
3.3  Methods 
3.3.1  Mice   
C57BL/6, CD45.1+ C57BL/6, Rag1−/− and DblGata1 (Balb/c background) mice 
were obtained from Jackson Labs. Rag2−/−, Rag2−/− cy−/−, Il33+/+, Balb/c and 
Il4ra−/− (Balb/c background) mice were obtained from Taconic.  Il33−/− mice were 
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provided by Amgen Inc via Taconic.  All mice were males and had ad libitum 
access to food and water and were maintained in a specific pathogen free facility 
with a 12h:12h light:dark cycle (lights on at 7:00 AM, lights off at 7:00 PM).  
Animals were randomly assigned to groups of n=3-5 mice per group per 
experiment, and at least two independent experiments were performed 
throughout.  In all in vivo experiments, a single technical replicate per mouse was 
performed.  For all in vitro experiments, 2-3 technical replicates were performed 
in each independent experiment.  Sample sizes in each independent experiment 
were selected to have power of at least 90% using published sample size/power 
formulas (Brestoff and Van den Broeck, 2013). All experiments were carried out 
under the guidelines of the Institutional Animal Care and Use Committee at the 
University of Pennsylvania. 
 
3.3.2  Rodent chow and diet-induced obesity  
In all experiments, mice had ad libitum access to food and water. Where 
indicated, mice were fed a control diet (CD, 10% kcal fat, Research Diets, New 
Brunswick, New Jersey) for the indicated period of time starting at 6-8 weeks of 
age.  CD was gamma-irradiated (10-20 kGy) and stored at 4 °C under dry 
conditions until use, and rodents were provided fresh chow weekly.  In all 
experiments that did not employ CD, mice were fed a standard autoclavable 
rodent chow (5% kcal fat, #5010, Lab Diets, St. Louis, Missouri) that had been 
autoclaved and allowed to cool overnight before use.  
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3.3.3  In vivo cytokine and enkephalin peptide treatments.   
Mice were administered 12.5 µg/kg carrier-free recombinant murine IL-33 (rmIL-
33, R&D Systems, Minneapolis, Minnesota) in sterile phosphate buffered saline 
(PBS) by intraperitoneal (i.p.) injection daily for the indicated number of days. In 
some studies, mice were treated with a previously reported dose (Zagon et al., 
2010) of 10 mg/kg [Met5]-enkephalin acetate salt hydrate (MetEnk, amino acid 
sequence YGGFM, ≥95.0% purity by HPLC, Sigma Aldrich, St. Louis, MO) in 
PBS or with PBS alone by bilateral subcutaneous injection near the iWAT daily 
for 5 days (approximately 200 µL per side). MetEnk or vehicle injections were 
performed under 2% isoflurane anesthesia. All injections were performed 
between the hours of 4:00 PM and 7:00 PM. 
 
3.3.4.  Tissue oxygen consumption 
A ~20 mg biopsy of iWAT was isolated from directly below the lymph node and 
minced in PBS containing 2% BSA, 1.1 mM sodium pyruvate and 25 mM 
glucose. Samples were placed in an MT200A Respirometer Cell (Strathkelvin), 
and oxygen consumption was measured for approximately 5 min. Oxygen 
consumption rates were normalized to minced tissue weight. 
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3.3.5  Isolation of immune cells from adipose 
Murine epididymal white adipose tissue (E-WAT), inguinal WAT (iWAT) or brown 
adipose tissue (BAT) or human subcutaneous abdominal WAT were harvested 
and dissected so as to be free of reproductive tissues, lymph nodes and fibrous 
connective tissue.  Tissues were finely minced using sterile scissors to form a 
slurry that was subsequently digested with 0.1% collagenase type II (Sigma-
Aldrich, USA) in high glucose DMEM at 37°C with shaking at 200 rpm for 60-90 
min at a 45° angle.  Digested tissues were filtered through a 70 µm nylon mesh.  
The mesh was washed with approximately 20 mL Wash Media (high glucose 
DMEM supplemented with 5% heat-inactivated fetal bovine serum [FBS], 100 
units/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine).  All Wash 
Media reagents were from Life Technologies (Grand Island, NY) except FBS, 
which was from Denville USA.  Washed cells were centrifuged at 500 x g for 5 
min at 4 °C, and then floating adipocytes were removed by aspiration and the 
stromal vascular fraction (SVF) pellet was resuspended in red blood cell lysis 
buffer (ACK RBC Lysis Buffer) and allowed to incubate at room temperature for 2 
min.  The RBC Lysis reaction was stopped by addition of 10 volumes Wash 
Media, and the SVF cells were recovered by centrifugation at 500 x g for 5 min at 
4 °C.  Cells were resuspended in 200 µL Wash Media and aliquotted in equal 
parts for immediate flow cytometric analysis or for re-stimulation as described 
below for subsequent intracellular cytokine analysis by flow cytometry.  In some 
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experiments, all recovered SVF cells were used for immediate flow cytometric 
analyses. 
 
3.3.6  Surface and nuclear staining of murine cells for flow cytometric 
analyses   
Isolated SVF cells from mice were resuspended in 100 µL FACS PBS (sterile 1X 
phosphate buffered saline [Invitrogen] supplemented with 2% heat-inactivated 
FBS and 1 mM EDTA [Invitrogen] containing LIVE/DEAD Fixable Aqua Dead Cell 
Stain (1:600) and anti-mouse IL-33R-biotin (T1/S2, clone DJ8) from MD 
Bioproducts (St. Paul, MN) (1:300).  Cells were incubated on ice for 30 min in the 
dark and were washed twice in 250 µL FACS PBS with centrifugation at 500 x g 
for 5 min at 4 °C before each wash.  Washed cells were stained with 
combinations of the following antibodies (all of which were used at 1:300 dilutions 
unless otherwise noted) in a volume of 90 µL staining buffer (FACS PBS 
supplemented with 20 µg/mL rat IgG): anti-mouse CD45-eFluor 605NC (clone 
30-F11; 1:200), CD45.1-eFluor 450 (A20; 1:100), CD45.2-AlexaFluor 700 (104), 
F4/80-eFluor 450 (BM8), CD3e-PerCP-Cy5.5 (145-2C11), CD5-PerCP-Cy5.5 
(53-7.3), CD19-PerCP-Cy5.5 (1D3), NK1.1-PerCP-Cy5.5 (PK136), CD11c-
PerCP-Cy5.5 (N418), FcεRIα-FITC (MAR-1), Foxp3-FITC (FJK-16s; 1:100), 
GATA-3-PE (TWAJ; 1:100) and CD25-PE-Cy7 (clone PC61.5) from eBioscience 
(San Diego, CA); CD11b-PE-Texas Red (M1/70.15; 1:500) from Life 
Technologies (Grand Island, NY); CD90.2-Alexa Fluor 700 (30-H12; 1:400) and 
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CD4-Brilliant Violet-650 (RM4-5) from BioLegend (San Diego, CA); SiglecF-PE 
(E50-2440) and CD3e-PE-CF594 (145-2C11) from BD Biosciences (San Jose, 
CA); CD206-Alexa Fluor 647 (MR5D3; 1:200) from AbD Serotec (Raleigh, NC); 
and Streptavidin-APC (1:300) from eBioscience. CD206 staining was performed 
following fixation and permeabilization with the Foxp3 Staining Buffer Set 
(eBioscience) according to the manufacturer’s protocol.  All intracellular stains 
were performed in 1X Permeabilization Buffer (PB, eBioscience) for 45 min on 
ice.  Cells were washed 3 times in 250 µL 1X PB with centrifugation at 500 x g for 
5 minutes at 4 °C between washes, and recovered cells were resuspended in 
200 µL FACS Buffer before flow cytometric analyses. 
 
3.3.7  Intracellular cytokine analysis 
To examine ILC2 MetEnk production, ILC2s were sort-purified from E-WAT of IL-
33-treated mice, as described below.  Ten thousand ILC2s were re-stimulated for 
4 days with rmIL-2 (10 ng/ml) and rmIL-7 (10 ng/mL) in the presence or absence 
of rmIL-33 (30 ng/mL) in complete media (Wash Media with 10% FBS, 55 µM 2-
mercaptoethanol and 25 mM HEPES) at 37 °C with 5% CO2.  All cytokines were 
from R&D Systems (Minneapolis, Minnesota).  During the final 4 hours of 
treatment, cells were treated with Brefeldin A (10 µg/mL) (Sigma-Aldrich) and 
monensin (1:1500) in a 37°C incubator (5% CO2).  Cells were then surface 
stained and fixed/permeabilized using Cyto Fix/Perm (BD Pharmingen) according 
to manufacturer’s instructions before intracellular staining with rabbit anti-mouse 
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MetEnk (bs-1759R, Bioss USA, Woburn, MA; 1:200) or rabbit anti-mouse IgG 
(Isotype control, Bioss USA; 1:200) followed by staining with goat anti-rabbit PE 
(sc-3739, 1:400; Santa Cruz Biotechnology, Dallas, TX).  All intracellular stains 
were performed in 1X Permeabilization Buffer (PB, eBioscience) for 45 min on 
ice.  After each intracellular stain, cells were washed 3 times in 250 µL 1X PB 
with centrifugation at 500 x g for 5 minutes at 4 °C between washes. Recovered 
cells after the final wash were resuspended in 200 µL FACS Buffer before flow 
cytometric analyses. 
 
3.3.8  Flow cytometry 
For all flow cytometry analyses, stained cells were acquired on a BD LSRII flow 
cytometer (BD Biosciences).  The entirety of each sample was acquired to obtain 
total cell counts, which were subsequently normalized to tissue weight.  Flow 
cytometry data were analyzed using FlowJo software version 9.6.4 (Tree Star, 
Inc.). 
 
3.3.9  Sort-purification and transfer of ILC2s 
E-WAT was harvested from male CD45.1+ C57BL/6 mice that received daily 
injections of rmIL-33 (12.5 µg/kg) for 7 days by intraperitoneal injection.  The 
stromal vascular fraction (SVF) was isolated as described above, and Live 
CD45+ Lin− CD25+ IL-33R+ ILC2s were sort-purified using an Aria Cell Sorter 
(BD) to ≥98% purity.  The lineage cocktail for sorts included CD3, CD5, CD19, 
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NK1.1, CD11c, CD11b, FcεERIα and SiglecF. CD45.1+ ILC2s (105) were 
immediately transferred to the indicated recipient mice by intraperitoneal injection 
(5 x 104 cells) and by subcutaneous injection near iWAT (5 x 104 cells split evenly 
for bilateral injections).  Daily transfers were performed for 4 consecutive days, 
and tissues were harvested on day 5.  In ILC2 reconstitution experiments 
involving Rag2−/− γc−/− recipient mice, 105 CD45.1+ ILC2s were transferred by a 
single intraperitoneal injection, and the next day mice were treated with PBS or 
rmIL-33 (12.5 µg/kg) by daily intraperitoneal injection for 7 days.  In ILC2 transfer 
experiments involving recipient mice on a Balb/c background (DblGata1 or 
Il4ra−/−), donor ILC2s were sort-purified as described above from E-WAT of 
Balb/c mice that received daily injections of rmIL-33 (12.5 µg/kg) daily for 5-7 
days by intraperitoneal injection.  Balb/c ILC2s (105) were immediately 
transferred to the indicated recipient mice by intraperitoneal injection (5 x 104 
cells) and by subcutaneous injection near iWAT (5 x 104 cells split evenly for 
bilateral injections).  Daily transfers were performed for 4 consecutive days, and 
tissues were harvested on day 5.   
 
3.3.10  Histologic analysis 
Tissues were fixed in 4% paraformaldehyde in PBS for at least 48 hours at 4°C 
and embedded in paraffin before cutting 5 µm sections and staining with 
hematoxylin and eosin (H&E) or performing immunohistochemistry (IHC) with 
rabbit anti-UCP1 antibody (Abcam, ab10983).  For IHC, rehydrated sections 
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were microwaved in 10 mM citric acid buffer (pH 6.0) for antigen retrieval, and 
endogenous peroxidases were quenched with 3% hydrogen peroxide. Sections 
were blocked with Avidin D, biotin and protein blocking agent in sequential order 
followed by application of the anti-UCP1 antibody (1:500). A biotinylated anti-
rabbit antibody was used as a secondary antibody.  Horseradish peroxidase-
conjugated ABC reagent was applied, and then DAB reagent was used to 
develop the signal before counterstaining in hematoxylin and dehydrating the 
sections in preparation for mounting. Stained sections were visualized and 
photographed using a Nikon E600 brightfield microscope. 
 
3.3.11  Real-time PCR 
Adipose tissues were snap-frozen in 1.0 mL TRIzol (Invitrogen) and 
homogenized using a Tissue Lyser (Qiagen) with a 5mm RNase-free metal bead 
(Qiagen).  Homogenates were centrifuged at 10,000 x g for 15 min at room 
temperature, and 700 µL of the TRIzol interphase was collected to exclude the 
top lipid phase and cellular debris and genomic DNA in the pellet.  Chloroform 
(200 µL; Fisher Scientific) was added to the lipid-extracted TRIzol fraction and 
shaken vigorously for 15 seconds before benchtop incubation at room 
temperature for 2-3 min.  Samples were centrifuged at 10,000 x g for 15 min at 
room temperature, and the top aqueous phase was collected (250 µL) into tubes 
containing 500 µL isopropanol (Sigma Aldrich) to precipitate the RNA.  Samples 
were mixed gently by vortexing on setting 4 (of 10) for 3-5 seconds and allowed 
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to incubate at room temperature for 10 min.  Samples were then applied to 
RNeasy Mini columns (Qiagen), and RNA was purified and isolated in 
accordance with the manufacturer’s instructions.  Purified total RNA samples 
were eluted in 30-50 µL RNase-free water (Qiagen), and total RNA 
concentrations were determined using a Nanodrop 2000c (Thermo Scientific, 
Wilmington, DE).  
 
cDNA was synthesized in 20 µL reactions from 1.0 µg aliquots of RNA using 
Superscript II Reverse Transcriptase (Invitrogen) and oligo(dT) (Invitrogen) 
according to manufacturer’s instructions. cDNA was diluted with 180 µL 
nuclease-free water (Promega) before used.  Real-time PCR was performed 
using 10 µL reactions consisting of 5 µL Power SYBR Green 2X Master Mix 
(Applied Biosystems), 3 µL nuclease-free water (Promega or Qiagen), 1 µL 
diluted cDNA and 1 µL primers (1 µM).  Previously published primer sequences 
for murine Ucp117 and Qiagen Quantitect real-time PCR primers for β-actin, Il33, 
Penk, Oprd1 and Ogfr.  Reactions were performed in duplicate or triplicate using 
the 7500 Fast Real-Time PCR System (Applied Biosystems) or the QuantStudio 
6 Flex Real-Time PCR System (Applied Biosystems).  CT values were 
normalized to the endogenous housekeeping gene β-actin.  The ΔΔCT method 
was employed for all real-time PCR analyses with expression levels for each 
sample expressed relative to the average gene expression level of the indicated 
control group. 
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3.3.12  Microarrays and ILC2 vs ILC3 gene enrichment analyses 
Microarray analyses (~25,000 genes) were performed using previously published 
microarray datasets (GEO GSE46468) (Monticelli et al., 2011).  In brief, Lin- 
CD90+ CD25+ IL-33R+ ILC2s from the lung (4 biological replicates each 
comprising 6 pooled lungs) and Lin- CD90+ CD25+ CD4+ ILC3s from the spleen 
(4 biological replicates each comprising 10 pooled spleens) were sorted using a 
FACS Aria (BD) directly into TRIzol LS (Invitrogen) at a purity of >97% (1.5-2.0 x 
104 cells/replicate). mRNA was isolated, amplified, labeled and hybridized to 
Affymetrix GeneChip (Mouse Gene 1.0 ST) as described previously (Monticelli et 
al., 2011). Gene expression Z-scores were calculated for each of 69 obesity-
associated genes in ILC2s or ILC3s (see Table 2 for a complete list of genes).  
First, the average and standard deviation of all microarray probe intensities were 
calculated for each cell type.  The average probe intensity of the array was 
subtracted from average probe intensity of each of the 69 obesity-associated 
genes.  The difference in average probe intensities (single gene minus array) 
was divided by the array standard deviation to calculate the Z-score.  Genes that 
were significantly enriched compared to the average gene expression level of the 
entire microarray dataset in one cell population but not the other (Z > +2.20) were 
considered to be differentially enriched in that cell population.  The Bonferroni 
correction was used to determine the level of significance with 69 comparisons to 
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account for multiple testing (α=0.05; k=69).  The Bonferroni-corrected P-value for 
level of significance was P = 0.014, which corresponds to a Z-score of ±2.20.  
 
3.3.13  Primary adipocyte culture 
iWAT or BAT was dissected from 4 week-old C57BL/6 mice (n=5 per experiment, 
pooled) and digested as described above. Stromal vascular fraction (SVF) cells 
were plated in 12-well CellBind plates, and adherent cells were grown to 
confluence. Cells were differentiated into adipocytes as previously described 
(Seale et al., 2011).  Briefly, cells were cultured for 2 days with 850 nM insulin, 1 
nM T3, 1 µM rosiglitazone, 125 nM indomethacin (125 µM for BAT primary 
adipocytes), 0.5 mM isobutylmethylxanthine (IBMX) and 1 µM dexamethasone in 
adipocyte culture media (DMEM:F12 [50:50] supplemented with 10% heat-
inactivated FBS, penicillin, streptomycin and L-glutamine). Cells were then 
maintained in adipocyte culture media supplemented with 850 nM insulin and 1 
nM T3 with either PBS or 50 µM MetEnk for 6 days, with fresh media 
replacement every 2 days. Cells were harvested on day 8 in TRIzol. 
 
3.3.14  Statistical analyses 
All data are expressed as mean ± standard error of the mean (SEM), except 
some human subject data that are expressed as proportions.  Statistical 
significance was determined using the two-tailed Student’s t test or a one-way or 
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two-way analysis of variance (ANOVA) followed by Sidak or Tukey post-hoc 
tests.  If variance differed between groups, the appropriate statistical correction 
was applies (e.g. Welch’s correction).  Correlation analyses were conducted 
using Pearson linear regression. Proportions among human samples were 
compared by χ2 tests.  Significance was set at P<0.05 except for microarray 
analyses, in which case the Bonferroni correction was applied to account for 
multiple testing (α=0.05, k=69), resulting in a level of significance of P<0.014.  
Statistical analyses were performed with Prism 6 (GraphPad Software, Inc.) or 
SPSS Statistics version 22 (IBM). 
 
3.4  Results 
3.4.1  IL-33 regulates beiging of white adipose tissue 
Given the thermogenic properties of beige and brown adipocytes (Harms and 
Seale, 2013; Pfeifer and Hoffmann, 2014; Rosen and Spiegelman, 2014; Wu et 
al., 2013), we tested whether IL-33 treatment regulates the morphology or Ucp1 
expression levels in WAT and BAT. In PBS-treated controls, E-WAT and iWAT 
from PBS-treated mice exhibited predominantly unilocular white adipocytes, and 
iWAT had interspersed paucilocular beige adipocytes that are characterized 
morphologically by multiple small lipid droplets and increased UCP1+ cytoplasm 
(Fig 19a).  Mice receiving rmIL-33 exhibited increased UCP1+ beige adipocytes 
in E-WAT and iWAT compared to PBS-treated controls (Fig. 19a).  In addition, 
expression levels of Ucp1 in E-WAT and iWAT were significantly increased in 
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mice treated with rmIL-33 compared to controls (Fig. 19b).  These results 
suggest that IL-33 can promote beiging of WAT.  rmIL-33 also resulted in 
increased frequencies (Fig. 20a) and numbers (Fig. 20b) of Lin− CD25+ IL-33R+ 
ILC2s in BAT.  However, in contrast to WAT, BAT from rmIL-33-treated mice 
exhibited decreased Ucp1 expression (Fig. 20c) without apparent morphologic 
changes to brown adipocytes  (Fig. 20d,e). Taken together, these results indicate 
that the stimulatory effect of rmIL-33 treatment on UCP1 expression was 
selective to WAT but not BAT.  
 
To further test whether IL-33 regulates beiging, we examined WAT morphology 
and Ucp1 expression levels of Il33+/+ versus Il33−/− mice that had been fed a 10% 
fat diet for 12 weeks. iWAT from Il33+/+ mice was predominantly comprised of 
white adipocytes with interspersed UCP1+ beige adipocytes (Fig. 21a), whereas 
iWAT from Il33−/− mice had few beige adipocytes (Fig. 21b).  Consistent with this, 
Ucp1 expression was significantly lower in iWAT of Il33−/− mice compared to 
Il33+/+ controls (Fig. 21c).  These findings indicate that endogenous IL-33 is a 
critical regulator of beiging.  
 
3.4.2  IL-33-elicited ILC2s are sufficient to drive beiging of white adipose 
tissue 
To test whether IL-33-elicited ILC2s can promote beiging, congenically marked 
CD45.1+ ILC2s from E-WAT of IL-33-treated donor mice were sort-purified and 
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adoptively transferred into wildtype CD45.2+ recipient mice (Fig. 22a). CD45.1+ 
donor ILC2s could be identified in iWAT of mice that received ILC2s but not 
control mice that received PBS (Fig. 22b), and total ILC2 numbers were 
significantly increased in iWAT of mice receiving CD45.1+ ILC2s compared to 
controls (Fig. 22c).  Transferred ILC2s could also be identified in E-WAT but 
were not found in BAT, mesenteric lymph nodes or lung (Fig. 23), demonstrating 
selective accumulation of WAT-derived ILC2s in WAT of recipient mice.  Mice 
that received ILC2s had increased UCP1+ beige adipocytes (Fig. 22d) and 
augmented expression of Ucp1 (Fig. 22e) in iWAT compared to controls.  In 
addition, iWAT from mice that received ILC2s had elevated oxygen consumption 
(Fig. 22f) in iWAT.  Collectively, these results indicate that activated ILC2s can 
promote beiging in wildtype mice.   
 
ILC2s have been shown to regulate both T and B cell responses (Halim et al., 
2014; Mirchandani et al., 2014; Moro et al., 2010; Oliphant et al., 2014), and IL-
33 treatment is associated with increased regulatory T cells (Treg) responses in 
mice (Schiering et al., 2014), a cell population previously implicated in regulation 
of metabolic homeostasis in obese mice (Cipolletta et al., 2012; Zhong et al., 
2014) (Feuerer et al., 2009).  Therefore we sought to test whether transferring IL-
33-elicited ILC2s could promote beiging in the absence of an adaptive immune 
system.  CD45.1+ donor ILC2s could be identified in iWAT of CD45.2+ Rag1−/− 
recipients that received ILC2s (Fig. 24a), and this was associated with increased 
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ILC2 numbers in iWAT compared to controls (Fig. 24b).  Similar to wildtype 
recipients, Rag1−/− hosts demonstrated increased UCP1+ beige adipocytes (Fig. 
24c) and upregulated expression of Ucp1 in iWAT (Fig. 24d) following ILC2 
transfer.  These data indicate that IL-33-elicited ILC2s are sufficient to promote 
beiging in the absence of the adaptive immune system. 
 
3.4.3  IL-33 may promote beiging in an ILC2-dependent manner 
The findings that IL-33 treatment and ILC2 transfer could promote beiging of 
WAT provoked the hypothesis IL-33 promotes beiging in an ILC2-dependent 
manner.  To test this, we first sort-purified ILC2s from IL-33-treated CD45.1+ 
mice and reconstituted Rag2−/− γc−/− mice with ILC2s by a single adoptive 
transfer by intraperitoneal injection. The next day, ILC2-sufficient Rag2−/− mice, 
ILC2-deficient Rag2−/− γc−/− mice and ILC2-reconstituted Rag2−/− γc−/− mice were 
treated with PBS or rmIL-33 daily for 7 days (Fig. 25a).  Following IL-33 
treatment, ILC2-sufficient Rag2−/− control mice but not ILC2-deficient Rag2−/− 
γc−/− mice demonstrated population expansion of E-WAT ILC2s (Fig. 25b,c).  
Furthermore, Rag2−/− γc−/− mice supported accumulation and IL-33-induced 
population expansion of donor ILC2s in host E-WAT (Fig. 25b,c).  IL-33 treatment 
increased expression of Ucp1 in E-WAT of ILC2-sufficient Rag2−/− mice but not 
ILC2-deficient Rag2−/− γc−/− mice treated with rmIL-33 (Fig. 25d).  Strikingly, IL-
33-induced increases in expression of Ucp1 and beiging were restored in ILC2-
reconstituted Rag2−/− γc−/− mice (Fig. 25d,e).  Collectively, these results indicate 
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that IL-33-induced beiging of WAT requires a γc-dependent cell population and 
that ILC2s are sufficient to rescue this defect, suggesting that IL-33-induced 
beiging is critically dependent on ILC2s. 
 
3.4.4  IL-33 and ILC2s can elicit beiging independently of eosinophils and 
the IL-4 receptor  
In addition to regulating adaptive immune cell responses, ILC2s are known to 
promote eosinophil and alternatively-activated macrophage (AAMac) responses 
in multiple tissue compartments including WAT(Molofsky et al., 2013; Wu et al., 
2011).  Recent studies indicate that eosinophils and IL-4Rα-dependent AAMac 
responses are critical for beiging in the context of chronic exposure to cold 
environmental temperatures (Qiu et al., 2014).   We therefore tested whether IL-
33 or ILC2s could elicit beiging of WAT independently of eosinophils or IL-4Rα.  
At steady state, UCP1+ beige adipocytes could be identified in iWAT of Balb/c 
(wildtype), DblGata1 mice (that lack eosinophils) and Il4ra−/− mice (that have 
dysregulated AAMac responses), and rmIL-33 treatment was associated with 
elevated ILC2 responses in iWAT and increased UCP1+ beige adipocytes in 
each of these strains (Fig. 26a-f).  Further, adoptive transfer of IL-33-elicited 
ILC2s was sufficient to promote beiging in DblGata1 and Il4ra-/- mice (Fig. 27a-d). 
Eosinophils are reported to be increased in iWAT from mice exposed to cold 
environmental conditions (Qiu et al., 2014; Rao et al., 2014), and ILC2s control 
eosinophils responses in multiple tissues including WAT (Molofsky et al., 2013; 
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Nussbaum et al., 2013).  However, exposure of C57BL/6 mice to 4 °C 
temperatures for 72 hours resulted in upregulation of Ucp1 expression (Fig. 28a) 
without altering the numbers of ILC2s (Fig. 28b) or expression of Il33 (Fig. 28c) in 
iWAT or BAT.  Thus, while eosinophils and AAMacs may contribute to optimal 
beiging under some physiologic settings such as chronic exposure to severe cold 
environmental temperatures (Qiu et al., 2014; Rao et al., 2014), these data 
indicate that the IL33/ILC2 axis can promote beiging independently of the 
eosinophil/IL-4Rα/AAMac pathway and may be associated with beiging in other 
physiologic contexts.  
 
3.4.5  ILC2s express methionine-enkephalin peptides that are upregulated 
by IL-33 treatment 
Obesity is associated with both decreased ILC2s (Chapter 2) and defective beige 
adipocytes (Carey et al., 2013; Cohen et al., 2014; Molofsky et al., 2013; Saito et 
al., 2009).  To address whether ILC2s produce obesity-associated factors that 
could regulate beiging, we employed genome-wide transcriptional profiling of 
ILC2s versus group 3 ILCs (ILC3s), a related innate immune cell population 
(Constantinides et al., 2014; Diefenbach et al., 2014; Monticelli et al., 2012; Spits 
and Cupedo, 2012), to compare gene expression enrichment scores of 69 genes 
previously linked to human obesity (Fig. 29a and Table 2) (McCarthy, 2010; 
Walley et al., 2009).  This analysis identified that one gene, proprotein 
convertase subtilisin/kexin type 1 (Pcsk1) (also known as prohormone 
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convertase 1 [Pc1]), was significantly enriched in ILC2s but not ILC3s (Fig. 29b, 
P<0.01). PCSK1 is an endopeptidase involved in processing some prohormones 
into active forms (Seidah, 2011; Seidah et al., 2013), and loss-of-function 
mutations in both mice and humans are associated with increased susceptibility 
to obesity (Benzinou et al., 2008; Creemers et al., 2012; Lloyd et al., 2006) in 
association with decreased caloric expenditure (Lloyd et al., 2006).  Of the 
prohormones known to be processed by PCSK1, the most differentially 
expressed in ILC2s compared to ILC3s was Proenkephalin A (Penk) (Fig. 29c), 
which encodes endogenous opioid-like peptides such as methionine-enkephalin 
(MetEnk, also known as opioid growth factor [OGF]).  Production of MetEnk by 
ILC2s was confirmed by flow cytometric analysis of sort-purified ILC2s re-
stimulated with IL-2 and IL-7 (Fig. 29d). Following IL-33 stimulation of sort-
purified ILC2s, production of MetEnk peptides on a per-cell basis was increased 
(Fig. 29e).  Together, these findings demonstrate that ILC2s express 
Proenkephalin A and its processing machinery to produce enkephalin peptides. 
 
3.4.6  Methionine-enkephalin appears to have tissue-specific effects on 
white versus brown adipose tissue 
Tissue-level gene expression analyses in wildtype mice at steady state indicated 
that Il33 and Penk expression levels were increased in iWAT compared to BAT 
(Fig. 30a), and Il33 and Penk expression levels were correlated in iWAT but not 
BAT of naïve C57BL/6 mice (Fig. 30b).  In addition, expression of the MetEnk 
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receptor δ1 opioid receptor (Oprd1) was higher in iWAT compared to BAT, 
whereas expression of the other known MetEnk receptor opioid growth factor 
receptor (Ogfr) was lower in iWAT compared to BAT (Fig. 30c).  Together, these 
gene expression analyses suggest that there may be tissue-specific regulation of 
the IL-33/PENK/MetEnk receptor pathways in iWAT compared to BAT.  These 
data also suggest that there might be tissue-specific of effects of MetEnk in iWAT 
compared to BAT.  Consistent with this, MetEnk stimulation of cultured primary 
adipocytes from iWAT (Fig. 31a), but not cultured primary adipocytes from BAT 
(Fig. 31b), induced Ucp1 expression.  This suggests that MetEnk has a 
stimulatory effect on the expression of Ucp1 in adipocytes from iWAT but not 
BAT. 
 
3.4.7  Methionine-enkephalin administration is associated with increased 
beiging of white adipose tissue in vivo 
To test whether MetEnk can promote beiging in in vivo, MetEnk peptides (amino 
acid sequence YGGFM) were delivered by subcutaneous injection into wild-type 
mice.  MetEnk treatment was associated with elicitation of UCP1+ beige (Fig. 
32a) and upregulated expression of Ucp1 in iWAT (Fig. 32b).  These changes 
were associated with increased iWAT oxygen consumption (Fig. 32c), collectively 
indicating the formation of functional beige fat.  Consistent with this, MetEnk 
treatment was also associated with decreased iWAT mass (Fig. 32d).  These 
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changes were not associated with increased expression of Il-4 or Il-13 (Fig. 32e) 
or with altered eosinophil or AAMac numbers (Fig. 32f) in iWAT.   
 
3.5  Discussion 
In this Chapter, we demonstrate that IL-33 is a critical regulator of beiging of 
WAT.  IL-33-induced beiging was mediated by ILC2s, and IL-33-elicited ILC2s 
were sufficient to drive the formation of functional beige fat in wildtype mice.  In 
addition, IL-33 and ILC2s could elicit beiging in mice that lack an adaptive 
immune system, eosinophils or IL-4Rα signaling.  This suggests that the IL-
33/ILC2 axis has the capacity to promote beiging of WAT independent of T cells 
and the eosinophil/IL-4Rα/AAMac/norepinephrine pathway.  Employing analyses 
of obesity-associated genes, we identify that ILC2s produce the previously 
unappreciated effector molecule MetEnk.  Finally, we demonstrate that MetEnk 
can drive beiging in vivo and upregulate Ucp1 expression levels in primary 
adipocytes from iWAT.   
  
Previous studies indicate that the immune system can have an important role in 
the generation of beige adipose.  Specifically, eosinophils are suggested to be 
activated and produce IL-4 in iWAT of mice exposed to cold environmental 
temperatures (Qiu et al., 2014).  This leads to IL-4/IL-4Rα-dependent stimulation 
of AAMacs in iWAT to produce norepinephrine and possibly other 
catecholamines that elicit beiging and increase the metabolic rate of mice (Qiu et 
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al., 2014).  Meteorin-like (Metrnl) is a hormone produced by adipose and muscle 
tissue and elicits beiging in iWAT by inducing local eosinophil accumulation and 
AAMac activation (Rao et al., 2014).  Mice that lack eosinophils (DblGata1 
mutant mice) or IL-4/IL-13-dependent signaling (Il4/13−/− mice) have impaired 
Ucp1 upregulation following cold exposure (Qiu et al., 2014), and administration 
of exogenous Meteorin-like produces attenuated beiging in DblGata1 or STAT6-
deficient mice that have defective AAMacs (Rao et al., 2014).  However, cold 
exposure and exogenous Meteorin-like can elicit beiging in these strains albeit in 
a less efficient manner (Qiu et al., 2014; Rao et al., 2014).  This provokes the 
hypothesis that there are other pathways beyond the eosinophil/IL-
4Rα/AAMac/norepinephrine pathway that can contribute to beiging in mice.  
Consistent with this, we observe that IL-33 treatment or adoptive transfer of IL-
33-elicited ILC2s form E-WAT is sufficient to drive beiging of iWAT in wildtype 
mice as well as DblGata1 mice that lack eosinophils and IL-4Rα-deficient mice 
that have dysregulated AAMacs.  Although it is likely that eosinophils and 
AAMacs contribute to optimal beiging in some physiologic contexts such as cold 
exposure (Qiu et al., 2014; Rao et al., 2014), the data presented in this Chapter 
indicate that the IL-33/ILC2 axis can elicit beiging independently of these 
pathways.  
 
Supporting this, we identified that ILC2s produce the pentapeptide MetEnk and 
reveal a previously unappreciated role for MetEnk in stimulation of beiging in 
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vivo. Delivery of MetEnk peptides to mice elicited beiging of WAT without 
affecting the numbers of eosinophils or AAMacs, suggesting that the IL-
33/ILC2/MetEnk pathway might elicit beiging independently of these cell types.  
Consistent with this, treatment of primary adipocytes from iWAT with MetEnk 
increased Ucp1 expression levels, indicating a direct stimulatory effect of MetEnk 
on adipocytes.  Recent studies suggest that there are multiple developmental 
pathways to beige adipocytes, including differentiation form a bipotent 
white/beige pre-adipocyte (Lee et al., 2012) and transdifferentiation of mature 
white adipocytes to beige adipocytes (Barbatelli et al., 2010; Rosenwald et al., 
2013).  Future studies will be required to investigate the mechanisms through 
which MetEnk elicits beiging.   
 
MetEnk has previously been to be produced by neurons to limit anxiety, pain and 
aggression levels in mice (Konig et al., 1996) and to promote conditioned 
learning and addiction in mice (Tseng et al., 2013).  In addition to these neuronal 
processes, MetEnk was shown to act directly on adipocytes to stimulate lipolysis 
(Nencini and Paroli, 1981), indicating that this neuronal-associated peptide also 
has metabolic effects.  Importantly, lipolysis is critical for the maintenance of 
beige adipocyte function (Dong et al., 2013; Mottillo et al., 2012; Nguyen et al., 
2011).  Further, UCP1 functions as a long-chain fatty acid-proton symporter and 
employs long-chain fatty acids for efficient uncoupling (Fedorenko et al., 2012).  
Thus, while MetEnk upregulates Ucp1 transcript levels in adipocytes, the lipolytic 
 
 
102 
effects of MetEnk may also contribute to beiging and the regulation of beige 
adipocyte function.   
 
MetEnk peptides are derived from Proenkephalin A (PENK) via PCSK1-
dependent processing (Seidah, 2011; Seidah et al., 2013). Single nucleotide 
polymorphisms in PCSK1 have been previously linked to the development of 
obesity in humans (Benzinou et al., 2008; Creemers et al., 2012; Lloyd et al., 
2006), and this has been associated with PCSK1 effects on both food intake and 
energy storage (Lloyd et al., 2006).  Obesity has also been associated with 
decreased beige fat activation in humans (Carey et al., 2013; Saito et al., 2009), 
and murine studies demonstrate that defective beige fat leads to increased 
susceptibility to obesity (Cohen et al., 2014).  The previous Chapter indicated 
that decreased ILC2 responses in WAT are a conserved feature of obesity in 
mice and humans and suggested the IL-33/ILC2 pathway may be dysregulated in 
obese WAT.  In light of these findings, the data in the present Chapter suggest 
that PCSK1 mutations might affect weight gain through regulation of the 
PENK/MetEnk/beiging pathway.   
 
Collectively, the data in this Chapter provide the first demonstration that the IL-
33/ILC2 axis regulates metabolic homeostasis by eliciting beiging of WAT.  
Production of enkephalin peptides is a previously unrecognized effector 
mechanism employed by ILC2s to regulate metabolic homeostasis.  From an 
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evolutionary perspective, coupling ILC2-dependent innate immune effector 
functions with the maintenance of systemic metabolic homeostasis could provide 
a rapid, integrated multi-organ response that allows mammals to surmount 
multiple environmental challenges including infection, nutrient stress or changes 
in temperature.  Given that impaired UCP1 and beige adipocyte function is 
associated with increased weight gain and obesity in mice (Cohen et al., 2014; 
Feldmann et al., 2009) and that activity of brown/beige (Sharp et al., 2012; Wu et 
al., 2012) adipose tissue is dysregulated in obese patients (Carey et al., 2013; 
Saito et al., 2009), targeting the IL-33/ILC2/beiging pathway could represent a 
new approach for treating obesity and obesity-associated diseases. 
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3.6  Tables and Figures 
 
Table 2.  List of genes with single nucleotide polymorphisms associated 
with human obesity  
Human 
gene 
symbol Human gene name 
Murine 
ortholog 
gene 
symbol 
Inclusion  
in 
Microarray 
ADAMTS9 
A disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 9 Adamts9 Yes 
BCDIN3D BCDIN3 domain containing Bcdin3d Yes 
BDNF Brain-derived neurotrophic factor Bdnf Yes 
CADM2 Cell adhesion molecule 2 Cadm2 Yes 
CNR1 Cannabinoid type 1 receptor Cnr1 Yes 
CPEB4 
Cytoplasmic polyadenylation element 
binding protein 4 Cpeb4 Yes 
CTNNBL1 Catenin, beta like 1 Ctnnbl1 Yes 
DLK1 Delta-like homologue 1 Dlk1 Yes 
ENPP1 
Ectonucleotide 
pyrophasphatase/phosphodiesterase 
1 Enpp1 Yes 
ETV5 Ets variant 5 Etv5 Yes 
FAIM2 Fas apoptotic inhibitory molecule 2 Faim2 Yes 
FANCL 
Fanconi anemia, complementation 
group L Fancl Yes 
FTO fat mass and obesity associated Fto Yes 
GHSR 
Growth hormone receptor 
secretogogue receptor Ghsr Yes 
GIPR 
Gastric inhibitory polypeptide 
receptor Gipr Yes 
GNPDA2 
Glucosamine-6-phosphate 
deaminase 2 Gnpda2 Yes 
GPRC5B 
G protein-coupled receptor, family C, 
group 5, member B Gprc5b Yes 
GRB14 
Growth factor receptor-bound protein 
14 Grb14 Yes 
HMGA1 High mobility group AT-hook 1 Hmga1 Yes 
HMGCR 
3-hydroxy-3-methylglutaryl-CoA 
reductase Hmgcr Yes 
HOXC13 Homeobox C13 Hoxc13 Yes 
ITPR2 
Inositol 1,4,5-trisphosphate receptor, 
type 2 Itpr2 Yes 
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KCTD15 
Potassium channel tetramerization 
domain containing 15 Kctd15 Yes 
KLF7 Kruppel-like factor 7 Klf7 Yes 
LEP Leptin Lep Yes 
LEPR Leptin receptor Lepr Yes 
LMNA Lamin A/C Lmna Yes 
LRP1B 
Low density lipoprotein receptor-
related protein 1B Lrp1b Yes 
LINGO2 
(LRRN6C) 
Leucine rich repeat and Ig domain 
containing 2 Lingo2 Yes 
LY86 Lymphocyte antigen 86 Ly86 Yes 
LYPLAL1 Lysophospholipase-like 1 Lyplal1 Yes 
MAF 
v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog Maf Yes 
MAP2K5 
Mitogen-activated protein kinase 
kinase 5 Map2k5 Yes 
MC4R Melanocortin 4 receptor Mc4r Yes 
MSRA Methionine sulfoxide reductase A Msra Yes 
MTCH2 Mitochondrial carrier 2 Mtch2 Yes 
MTIF3 
Mitochondrial translational initiation 
factor 3 Mtif3 Yes 
MTMR9 Myotubularin related protein 9 Mtmr9 Yes 
NAMPT 
Nicotinamide 
phosphoribosyltransferase Nampt Yes 
NCR3 
Natural cytotoxicity triggering 
receptor 3 Ncr3           No 
NEGR1 Neuronal growth regulator 1 Negr1 Yes 
NFE2L3 Nuclear factor, erythroid 2-like 3 Nfe2l3 Yes 
NPC1 Niemann-Pick disease, type C1 Npc1 Yes 
NPY2R Neuropeptide Y receptor Y2 Npy2r Yes 
NRXN3 Neurexin 3 Nrxn3 Yes 
PCSK1 
Proprotein convertase subtilisin/kexin 
type 1 Pcsk1 Yes 
PIGC 
Phosphatidylinositol glycan anchor 
biosynthesis, class C Pigc Yes 
POMC Proopiomelanocortin Pomc Yes 
PRKD1 Protein kinase D1 Prkd1 Yes 
PRL Prolactin Prl Yes 
PTBP2 Polypyrimidine tract binding protein 2 Ptbp2 Yes 
PTER Phosphotriesterase related Pter Yes 
RSPO3 R-spondin 3 Rspo3 Yes 
SDCCAG8 
Serologically defined colon cancer 
antigen 8 Sdccag8 Yes 
SEC16B SEC16 Homolog B Sec16b Yes 
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SH2B1 SH2B adaptor protein 1 Sh2b1 Yes 
SLC39A8 
Solute carrier family 39 (zinc 
transporter), member 8 Slc39a8 Yes 
SNRPN 
Small nuclear ribonucleoprotein 
polypeptide N Snrpn Yes 
SOCS1 Suppressor of cytokine signaling 1 Socs1 Yes 
SOCS3 Suppressor of cytokine signaling 3 Socs3 Yes 
STAB1 Stabilin 1 Stab1 Yes 
TBC1D1 
TBC1 (tre-2/USP6, BUB2, cdc16) 
domain family, member 1 Tbc1d1 Yes 
TBX15 T-box 15 Tbx15 Yes 
TFAP2B 
Transcription factor AP-2 beta 
(activating enhancer binding protein 2 
beta) Tfap2b           No 
TMEM160 Transmembrane protein 160 Tmem160 Yes 
TMEM18 Transmembrane protein 18 Tmem18 Yes 
TNNI3K TNNI3 interacting kinase Tnni3k Yes 
TUB Tubby bipartite transcription factor Tub Yes 
VEGFA Vascular endothelial growth factor A Vegfa Yes 
ZNF608 Zinc finger protein 608 Zfp608 Yes 
ZNRF3 Zinc and ring finger 3 Znrf3 Yes 
 
 
 
107 
  
 
Figure 19.  Administration of recombinant murine IL-33 is 
associated with increased beiging of white adipose tissue (WAT).  
Wildtype C57BL/6 mice were treated with PBS or recombinant murine 
IL-33 (12.5 µg/kg/day) by intraperitoneal injection for 7 days.  (a) 
Epididymal (E)-WAT and inguinal (i)WAT Uncoupling protein 1 (UCP1) 
immunohistochemistry.  Scale bars, 100 µm.  (b) Ucp1 transcript levels 
in E-WAT and iWAT. Student’s t-test,  *P<0.05, ***P<0.001. 
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Figure 20.  Brown adipose tissue (BAT) contains Lin− CD25+ IL-33R+ 
ILC2s that expand in response to IL-33 in association with decreased 
Ucp1 expression.  C57BL/6 male mice (10 weeks old) were treated with 
PBS (n=8) or IL-33 (12.5 µg/kg, n=8) daily by intraperitoneal injection for 7 
days. (a)  Representative plots and frequencies of Lin− CD25+ IL-33R+ 
ILC2s in interscapular BAT. Gated on live CD45+ Lin− cells. (b) Numbers of 
ILC2s per gram of BAT.  (c) Ucp1 expression in BAT by real-time PCR.  (d)  
Uncoupling protein 1 (UCP1) immunohistochemistry of BAT at 10X 
magnification. Scale bars, 100 µm.  (e) 40X magnification of panel d. Scale 
bars, 100 µm.  Student’s t-test, *<0.05, ***P<0.001. 
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Figure 21. IL-33-deficient mice exhibit defective beiging of white 
adipose tissue (WAT). (a-c) Il33+/+ (n=6) or Il33−/− (n=5) mice were fed a 
low fat diet (10% kcal fat) for 12 weeks starting at age 7 weeks.  Uncoupling 
protein 1 (UCP1) immunohistochemistry (IHC) in inguinal (i)WAT from (a) 
Il33+/+ or (b) Il33−/− mice.  Scale bars, 100 µm.  (c) Ucp1 transcript levels in 
iWAT.   
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Figure 22.  Adoptive transfer of IL-33-elicited ILC2s is sufficient to 
drive beiging.  (a) Experimental design for panels b-f. Live CD45+ Lin− 
CD25+ IL-33R+ ILC2s were sort-purified from E-WAT of CD45.1+ mice 
treated with 12.5 µg/kg recombinant murine (rm)IL-33 daily for 7 days by 
intraperitoneal injection. ILC2s (1 x 105 total) were transferred to 
CD45.2+ recipient mice daily for 4 days by subcutaneous injection near 
inguinal (i)WAT (5 x 104 ILC2s, split evenly bilaterally) and 
intraperitoneal injection (5 x 104 ILC2s). Tissues were harvested on day 
5 for analyses (PBS, n=8; ILC2, n=8 except panel f).  (b) Representative 
plots identifying donor and recipient ILC2s in iWAT.  Plots pre-gated on 
live CD45+ Lin− CD25+ IL33R+ cells.  Lineage cocktail: CD3, CD5, CD19, 
NK1.1, CD11c, CD11b and FcεRIα.  (c) Total numbers of ILC2s per 
gram iWAT.  (d) iWAT Uncoupling protein 1 (UCP1) 
immunohistochemistry, bar 100 µm.  (e) Ucp1 expression in iWAT.  (f) 
iWAT oxygen consumption (PBS, n=14; ILC2, n=15). 
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Figure 23.  IL-33-elicited ILC2s derived from white adipose tissue 
(WAT) selectively accumulate in recipient WAT.  Live CD45+ Lin− 
CD25+ IL-33R+ ILC2s were sort-purified from E-WAT of CD45.1+ mice 
treated with 12.5 µg/kg recombinant murine (rm)IL-33 daily for 7 days 
by intraperitoneal injection. ILC2s (1 x 105 total) were transferred to 
CD45.2+ recipient mice daily for 4 days by subcutaneous injection near 
iWAT (5 x 104 ILC2s, split evenly bilaterally) and intraperitoneal 
injection (5 x 104 ILC2s). Tissues were harvested on day 5 for 
analyses. (b) Donor and recipient ILC2s in E-WAT, brown adipose 
tissue (BAT), mesenteric lymph nodes (mLN) and lung. iWAT ILC2 
plots from this experiment are shown in the previous figure.  Pre-gated 
on Live CD45+ Lin− CD25+ IL-33R+ ILC2s.  Donor ILC2s are defined as 
CD45.1+ CD45.2−, whereas recipient ILC2s are defined as CD45.1− 
CD45.2+. Representative plots shown. Frequencies represent percent 
of ILC2s that are recipient or donor cells. Student’s t-test, ***P<0.001.   
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Figure 24.  IL-33-elicited ILC2s can elicit beiging independently 
of the adaptive immune system. Live CD45+ Lin− CD25+ IL-33R+ 
ILC2s were sort-purified from E-WAT of C57BL/6 mice treated with 
rmIL-33 (12.5 µg/kg) daily for 7 days by intraperitoneal injection.  
ILC2s (1 x 105 total) were transferred to Rag1−/− recipient mice on a 
C57BL/6 background daily for 4 days by subcutaneous injection (n=8 
mice per group). (a) Representative plots identifying donor and 
recipient ILC2s in iWAT.  Plots pre-gated on live CD45+ Lin− CD25+ 
IL33R+ cells.  Lineage cocktail: CD3, CD5, CD19, NK1.1, CD11c, 
CD11b and FcεRIα.  (b) Total numbers of ILC2s per gram iWAT.  (c) 
iWAT Uncoupling protein 1 (UCP1) immunohistochemistry, bar 100 
µm.  (d)  iWAT Ucp1 expression levels.  Student’s t-test, *P<0.05, 
**P<0.01. 
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Figure 25.  ILC2s from E-WAT accumulate in white adipose tissue 
(WAT) of recipient mice and expand in response to IL-33 to 
promote beiging. Experimental design for panels b-e. Sort-purified 
CD45.1+ ILC2s (105) from E-WAT of IL-33-treated mice (12.5 
µg/kg/day for 7 days by intraperitoneal [i.p.] injection) were transferred 
into Rag2−/− γc−/− recipients by a single i.p. injection. ILC2-sufficient 
Rag2−/− mice, ILC2-deficient Rag2−/− γc−/− mice and ILC2-reconstituted 
Rag2−/− γc−/− mice were treated with PBS or rmIL-33 (12.5 µg/kg) by 
intraperitoneal injection daily for 7 days (n=4 mice per group).  (b) 
Representative plots of live CD45.1+ Lin− CD25+ IL33R+ ILC2s in E-
WAT. Blue, recipient cells. Red, donor cells. Lineage cocktail includes 
CD3, CD5, CD19, NK1.1, CD11c, CD11b and FcεRIα.  (c) ILC2 
numbers per gram of E-WAT.  (d) Ucp1 expression in E-WAT.  (e) 
iWAT UCP1 immunohistochemistry, bar 100 µm.  ANOVA with Tukey 
post-hoc test, ***P<0.001. 
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Figure 26.  IL-33 treatment can elicit beiging independently of 
eosinophils and IL-4Rα signaling. 	  Wildtype (Balb/c), DblGata1 mice that 
lack eosinophils or Il4ra−/− mice that have dysregulated alternatively 
activated macrophages (AAMacs) (both mutant strains on a Balb/c 
background) were treated with PBS or recombinant murine (rm)IL-33 (12.5 
µg/kg) daily by intraperitoneal injection for 7 days.  (a) ILC2 numbers/gram 
iWAT and (b) iWAT UCP1 immunohistochemistry (IHC) in Balb/c mice. (c) 
iWAT ILC2 numbers per gram of adipose and (d) iWAT UCP1 IHC in 
DblGata1 mice. (e) ILC2 numbers/gram iWAT and (f) iWAT UCP1 IHC in 
Il4ra−/− mice.  Student’s t-test, *P<0.05. There were 3-6 mice per group 
from 2 independent experiments. Scale bars, 100 µm. 
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Figure 27.  IL-33-elicited ILC2s can promote beiging 
independently of eosinophils and IL-4Rα signaling.  Live CD45+ 
Lin− CD25+ IL-33R+ ILC2s were sort-purified from E-WAT of Balb/c 
mice treated with rmIL-33 (12.5 µg/kg) daily for 5-7 days by 
intraperitoneal injection. ILC2s (1 x 105 total) were transferred to the 
indicated recipient mice daily for 4 days by subcutaneous injection. (a) 
iWAT ILC2 numbers per gram of adipose and (b) iWAT Uncoupling 
protein 1 (UCP1) immunohistochemistry (IHC) in DblGata1 recipients.  
(c) iWAT ILC2 numbers per gram of adipose and (d) iWAT UCP1 IHC 
in Il4ra−/− recipients.  Student’s t-test, *P<0.05. Data are from n=3-6 
mice per group pooled over 2-3 independent experiments.  Scale bars, 
100 µm. 
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Figure 28.  Chronic exposure to severe cold environmental 
temperatures is not associated with accumulation of ILC2s in inguinal 
white adipose tissue (iWAT) or brown adipose tissue (BAT).  C57BL/6 
mice were single-housed at room temperature (n=7) or 4 °C (n=8) for 72 
hours.  (a)  Uncoupling protein 1 (Ucp1) mRNA levels in iWAT and BAT. (b) 
ILC2 numbers per gram of adipose tissue in iWAT and BAT. (c) Interleukin 
33 (Il33) mRNA levels in iWAT and BAT.  Student’s t-test, **P<0.01, 
***P<0.001.  
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Figure 29. ILC2s produce the obesity-associated gene PCSK1 and the 
PCSK1 target methionine-enkephalin.  (a) Gene expression enrichment 
analyses of 69 obesity-associated genes in ILC2s (x-axis) versus ILC3s (y-
axis).  Genes significantly enriched in one cell type but not the other are red.  
(b) Differential expression of PCSK1 target genes in ILC2s vs ILC3s.  (c) 
Intracellular staining of MetEnk (black line) or rabbit IgG isotype control 
(shaded histogram) in ILC2s sort-purified from E-WAT and re-stimulated in 
vitro with IL-2 and IL-7 (10 ng/mL) for 4 days.  (d) MetEnk mean 
fluorescence intensity (MFI) in sort-purified E-WAT ILC2s re-stimulated in 
vitro with IL-2 and IL-7 (10 ng/mL) with or without IL-33 (30 ng/mL) for 4 
days.  Isotype control MFI for each group was subtracted before calculating 
relative expression.  Shown are averages from 4 independent experiments, 
each representing pooled cells from n=3-5 mice and measured in duplicate 
or triplicate. 
 
 
118 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.  Interleukin 33 (Il33) and Proenkephalin A (Penk) 
expression levels are tissue specific.  (a) Il33 and Penk mRNA levels 
in inguinal white adipose tissue (iWAT) vs brown adipose tissue (BAT), 
n=8 mice, paired samples. (b) Il33 and Penk mRNA expression levels 
are correlated in iWAT but not BAT.  Linear regression, n=16 mice, 
naïve C57BL/6 mice.  (c) Ogfr and Oprd1 mRNA levels in inguinal white 
adipose tissue (iWAT) vs brown adipose tissue (BAT), n=8 mice, paired 
samples. For panels a and c, Paired Student’s t-test, *P<0.01, 
***P<0.001. For panel b, Pearson linear regression. 
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Figure 31.  Methionine-enkephalin (MetEnk) treatment upregulates 
Uncoupling protein 1 (Ucp1) expression in primary adipocytes from 
inguinal white adipose tissue (iWAT).  Adherent stromal vascular 
fraction (SVF) cells from (a) iWAT or (b) BAT of 4-week-old C57BL/6 
mice were differentiated into adipocytes for 2 days, treated with PBS or 
50 µM MetEnk from days 2-8 and harvested on day 8 (iWAT: n=7 PBS, 
n=8 MetEnk; BAT: n=6 PBS, n=6 MetEnk from 2-3 independent 
experiments).  Student’s t-test, **P<0.01. 
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Figure 32.  Methionine-enkephalin (MetEnk) treatment can elicit 
beiging in vivo.  Wildtype mice were treated with PBS (n=7) or MetEnk 
(n=9) by subcutaneous injection (10 mg/kg/day) for 5 days.  (a) 
Uncoupling protein 1 (UCP1) immunohistochemistry (IHC) in inguinal 
white adipose tissue (iWAT).  Scale bars, 100 µm.  (b) iWAT Ucp1 
expression, (c) iWAT oxygen consumption, (d) iWAT relative mass, (e) 
iWAT Il4 and Il13 expression and (f) numbers of eosinophils (Eos, live 
CD45+ SiglecF+ SSChi) and alternatively activated macrophages 
(AAMacs, live CD45+ SiglecF- F4/80+ CD206+) per gram of iWAT. 
Student’s t-test, *P<0.05, **P<0.01. 
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CHAPTER 4:  Summary, Discussion and Future Directions 
 
 
4.1  Characterization of Group 2 innate lymphoid cell responses in 
white adipose tissue  
Group 2 innate lymphoid cells (ILC2s) are a recently described immune cell type 
(Moro et al., 2009; Price et al., 2010; Neill et al. 2010) that respond to epithelial-
derived cytokines that include IL-33, IL-25 and thymic stromal lymphopoietin 
(TSLP) to initiate type 2 immune responses that promote host protective 
immunity against helminth pathogens or pathologic allergic inflammation (Kim, 
2014; Monticelli et al., 2012; Sonnenberg et al., 2013; Spits et al., 2013; Spits 
and Cupedo, 2012).  ILC2s initiate type 2 immune responses in multiple tissues 
by producing IL-5 and IL-13 that act to promote eosinophil and AAMac 
responses, respectively (Molofsky et al., 2013; Nussbaum et al., 2013), although 
these cells can also promote adaptive T helper type 2 (Th2) and B cell responses 
in some contexts (Halim et al., 2014; Mirchandani et al., 2014; Moro et al., 2010; 
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Oliphant et al., 2014).  Production of type 2 cytokines by ILC2s is critically 
regulated by the transcription factor GATA-3 (Furusawa et al., 2013; Mjosberg et 
al., 2012), a transcription factor that also controls ILC2 development (Monticelli et 
al., 2012; Sonnenberg et al., 2013; Spits and Cupedo, 2012).  Although ILC2 
responses are associated with immune responses at barrier surfaces such as the 
gut and lung, ILC2s were also recently demonstrated to be present in WAT, 
where these cells constitutively produce IL-5 and IL-13 to sustain eosinophils and 
AAMacs (Molofsky et al., 2013).  ILC2-mediated activation of the eosinophil/IL-
4/AAMac pathway in WAT has been implicated in limiting obesity (Hams et al., 
2013; Molofsky et al., 2013; Wu et al., 2011).  In addition, IL-33 has been shown 
to have protective effects on inflammatory responses in WAT and for limiting 
obesity (Miller et al., 2010).  Based on these findings, the goal of this thesis was 
to investigate ILC2 responses in WAT in the setting of murine and human obesity 
and the mechanisms through which the IL-33/ILC2 pathway influences metabolic 
homeostasis. 
 
The results presented in this thesis identify IL-33R+ GATA-3+ ILC2s in human 
and murine WAT and reveal a previously unappreciated link between IL-33-
dependent ILC2 responses and beiging of WAT.  In Chapter 2, decreased WAT 
ILC2 populations were found to be a conserved feature of obesity in humans and 
mice.  In mice, IL-33 was critical for promoting ILC2 responses in WAT and 
limiting the development of obesity in mice, and treatment of mice with IL-33 was 
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associated with increased metabolic rate.  In Chapter 3, IL-33 is shown to 
promote beiging of WAT in a process mediated by ILC2s.  IL-33-elicited ILC2s 
could drive beiging independently of the adaptive immune system and the 
eosinophil/IL-4Rα/AAMac pathway.  It was found that ILC2s produced 
methionine-enkephalin (MetEnk) peptides, which were sufficient to drive beiging 
in vivo and in vitro, indicating that the IL-33/ILC2 axis elicits beiging via 
production of MetEnk peptides. 
 
Previous studies have implicated ILC2s in limiting obesity in mice and have 
indicated that ILC2s in WAT can expand in response to exogenous IL-33 (Hams 
et al., 2013; Molofsky et al., 2013).  However, the relevance of ILC2 responses in 
human obesity remained unknown.  In addition, the endogenous factors that 
control ILC2 responses in WAT and the mechanisms through which ILC2s 
regulate metabolic homeostasis remain poorly understood.  In Chapter 2, using 
human subcutaneous WAT and murine epididymal (E)-WAT, we identified 
Lineage (Lin)− CD25+ CD127+ ILCs that were uniformly positive for the IL-33R+ 
GATA-3+ ILC2s in both species.  WAT ILC2 populations were decreased in both 
murine and human obesity, suggesting that there may be a conserved 
immunologic response in human and murine obesity that suppresses ILC2s.   
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The mechanisms of this decrease in ILC2s is not clear, however one possibility is 
that ILC2s become resistant to the effects of IL-33 (i.e., hypo-responsiveness to 
IL-33).  Consistent with this hypothesis are recent studies indicating that IL-33 
production is elevated in WAT of obese mice and humans (Zeyda et al., 2013), 
which would be expected to result in increased ILC2 responses rather than the 
observed decrease in ILC2s.  Supporting this possibility are data in Chapter 2 
indicating that endogenous IL-33 is necessary to sustain ILC2 responses in 
WAT.  Therefore, loss of IL-33-dependent signaling may contribute to decreased 
ILC2 responses in obesity.  Another possible explanation for why ILC2s are 
decreased in WAT may be related to decreases in other immune cell populations 
in WAT that produce factors that stimulate ILC2s.  For example, iNKT cells in 
WAT are decreased in obesity and produce substantial amounts of IL-4 (Lynch et 
al., 2014; Lynch et al., 2012), a factor that stimulates ILC2 proliferation and 
effector cytokine production in the skin and lung (Kim et al., 2014; Motomura et 
al., 2014).  Direct associations between iNKT and ILC2 responses have not been 
investigated.  In addition, alternative mechanisms that might decrease ILC2s in 
WAT are potential direct effects of fatty acids on ILC2s, or inflammatory signals 
from other immune cell populations that suppress ILC2 responses.  Future 
studies will be required to understand the mechanisms associated the decreased 
ILC2 response in WAT in the context of obesity. 
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IL-33 was previously shown to be an important regulator of adiposity and 
inflammation in obese WAT (Miller et al., 2010), and exogenous IL-33 has been 
shown to elicit ILC2 responses in WAT (Molofsky et al., 2013).  The studies in 
Chapter 2 support and extend these prior observations by indicating that 
endogenous IL-33 is necessary to sustain ILC2s and to limit the development of 
obesity.  Recent studies showed that antibody-mediated depletion of ILC2s is 
associated with increased weight gain and more severe insulin resistance in mice 
fed a high fat diet (Hams et al., 2013), and transferring IL-25-elicted ILC2s is 
sufficient to promote weight loss in diet-induced obese mice (Hams et al., 2013).  
This suggests that ILC2s negatively regulate the development of obesity, 
although the mechanisms of this remain poorly understood.  The studies in 
Chapter 2 indicate that administration of exogenous IL-33 promoted ILC2 
responses in WAT and decreased adiposity in association with increased energy 
expenditure.  This finding is consistent with earlier studies indicating that the 
eosinophil/IL-4Rα/AAMac pathway can regulate caloric expenditure of mice 
(Molofsky et al., 2013; Qiu et al., 2014; Rao et al., 2014; Wu et al., 2011).  
Therefore, it is likely that ILC2s regulate metabolic homeostasis by eliciting the 
eosinophil/IL-4Rα/AAMac pathway in WAT. 
 
4.2  IL-33 and ILC2s promote beiging of white adipose tissue 
Previous studies have indicated that the eosinophil/IL-4Rα/AAMac pathway 
regulates energy expenditure by eliciting beiging of WAT (Liu et al., 2014; Qiu et 
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al., 2014; Rao et al., 2014), a process in which UCP1-expressing beige 
adipocytes emerge within WAT (Bartelt and Heeren, 2014; Harms and Seale, 
2013; Rosen and Spiegelman, 2014; Wu et al., 2013).  Eosinophils are recruited 
to WAT in the setting of chronic exposure to severe cold environmental 
temperatures (4°C), and these cells produce IL-4 to elicit AAMac production of 
norepinephrine (Qiu et al., 2014; Rao et al., 2014).  Although ILC2s are known to 
be upstream mediators of eosinophil and AAMac responses in WAT (Molofsky et 
al., 2013), whether ILC2s can contribute to beiging was unknown.  Data in 
Chapter 3, indicate that IL-33 treatment and adoptive transfer of IL-33-elicited 
ILC2s derived from WAT are sufficient to promote beiging.  Surprisingly, 
however, the IL-33/ILC2 pathway could elicit beiging independently of 
eosinophils and IL-4Rα.  Gene expression enrichment analyses of obesity-
associated genes in ILC2s indicated that ILC2s express PCSK1, a gene 
previously linked to human and murine obesity by regulating both food intake and 
caloric expenditure (Benzinou et al., 2008; Lloyd et al., 2006) by processing 
various pro-hormones into their active forms (Seidah, 2011; Seidah et al., 2013).  
We found that ILC2s produce the PCSK1 target gene Proenkephalin A and its 
active form methionine-enkephalin, and this peptide could upregulate Ucp1 
expression in adipocytes in vitro and elicit beiging in vivo. 
 
Collectively, these findings suggest that ILC2s can elicit beiging via multiple 
mechanisms (Fig. 33).  First, ILC2s likely induce the eosinophil/IL-4Rα/AAMac 
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pathway to promote beiging via production of norepinephrine (NE).  In addition 
ILC2s can produce MetEnk peptides that can directly stimulate beiging.  It is not 
yet clear whether NE and MetEnk elicit the same beige adipocyte subset.  
However, we propose that NE and MetEnk cooperatively support optimal beiging 
to regulate metabolic homeostasis.  Supporting this are prior studies suggesting 
that NE and MetEnk signaling pathways might interact to cooperatively stimulate 
lipolysis in adipocytes (Nencini and Paroli, 1981), a process that is critical for 
beige adipocyte responses and UCP1 function (Fedorenko et al., 2012; Harms 
and Seale, 2013; Rosen and Spiegelman, 2014; Wu et al., 2013).  Future studies 
focused on MetEnk and NE interactions in adipocytes are warranted to better 
understand that mechanisms by which ILC2s, eosinophils and AAMacs 
contribute to the regulation of beiging and metabolic rate. 
 
Another possibility is that ILC2-derived MetEnk and AAMac-derived NE elicit 
distinct populations of beige adipocytes involved in the regulation of metabolic 
homeostasis in different physiologic contexts.  Supporting this, the eosinophil/IL-
4Rα/AAMac pathway is activated in WAT in the setting of chronic cold exposure 
(Qiu et al., 2014; Rao et al., 2014), whereas data in Chapter 3 indicate that ILC2 
numbers and Il33 expression were unchanged in iWAT following 3 days of 
exposure to severe cold environmental temperatures.  This suggests that the IL-
33/ILC2 pathway is not activated in the setting of cold exposure and that other 
factors such as the adipokine/myokine meteorin-like or IL-4/IL-13-producing iNKT 
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cells might elicit the eosinophil/AAMac-dependent beiging pathway (Lynch et al., 
2014; Lynch et al., 2012; Rao et al., 2014).  Other metabolic functions of beige 
adipocytes include limiting weight gain and promoting glucose homeostasis 
(Cohen et al., 2014).  As the IL-33/ILC2 axis appears to be dysregulated in the 
setting of obesity and to limit weight gain (Chapter 2), the IL-
33/ILC2/MetEnk/beiging pathway might be associated with regulation of weight 
gain or maintenance of glucose homeostasis.  Additional studies will be required 
to dissect the physiologic functions of ILC2s and MetEnk in the regulation of 
beiging. 
 
4.3  Concluding Remarks 
Previous studies have implicated various type 2 immune cells in the regulation of 
weight gain (see Chapter 1), and emerging work indicates that eosinophils and 
AAMacs can promote beiging of WAT through AAMac-derived norepinephrine to 
regulate energy expenditure (Liu et al., 2014; Qiu et al., 2014; Rao et al., 2014).  
ILC2s produce effector cytokines that elicit type 2 immune responses (Kim, 2014; 
Monticelli et al., 2012; Spits and Cupedo, 2012) and stimulate eosinophils and 
AAMacs through production of IL-5 and IL-13 (Molofsky et al., 2013).  Although 
ILC2s have been implicated in limiting weight gain by regulating the 
eosinophil/IL-4/AAMac pathway (Hams et al., 2013; Molofsky et al., 2013; Wu et 
al., 2011), the relevance of ILC2 responses in human obesity and the 
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mechanisms through which ILC2s regulate metabolic homeostasis have 
remained poorly understood. 
  
Collectively, the data presented in this thesis provide the first demonstration that 
dysregulated ILC2 responses in WAT are a conserved feature of obesity in 
humans and mice and that the IL-33-ILC2 axis regulates metabolic homeostasis 
by eliciting beiging of white adipose tissue.  The expression of enkephalin 
peptides within ILC2s indicates a previously unrecognized effector mechanism 
employed by ILC2s to regulate metabolic homeostasis. From an evolutionary 
perspective, coupling ILC2-dependent innate immune effector functions with the 
maintenance of systemic metabolic homeostasis through beiging of WAT could 
provide a rapid and integrated multi-organ response that allows mammals to 
surmount multiple environmental challenges including infection, nutrient stress or 
changes in temperature.  Given that impaired beige adipocyte function is 
associated with increased weight gain and obesity in mice (Cohen et al., 2014; 
Feldmann et al., 2009) and that activity of brown/beige (Sharp et al., 2012; Wu et 
al., 2012) adipose tissue is dysregulated in obese patients (Carey et al., 2013; 
Saito et al., 2009), targeting the IL-33-ILC2-beiging pathway could represent a 
new approach for the treatment of obesity and obesity-associated disorders such 
as type 2 diabetes and atherosclerosis. 
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4.4  Figures 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 33.  Summary model linking the IL-33/ILC2/MetEnk pathway 
to the regulation of beiging and obesity.   Interleukin (IL)-33 acts on 
group 2 innate lymphoid cells (ILC2s) to upregulate production of the 
effector molecules IL-5, IL-13 and enkephalin peptides.  ILC2-derived IL-
5 promotes eosinophil homeostasis in WAT, and eosinophils in turn 
produce IL-4 to sustain alternatively activated macrophages (AAMacs) in 
WAT.  ILC2-derived IL-13 can also promote AAMac responses.  In the 
setting of chronic exposure to a cold environment, eosinophil-derived IL-
4 stimulates AAMacs to produce catecholamines such as 
norepinephrine, which acts directly on beige adipocytes to upregulate 
uncoupling protein 1 (UCP1) expression and promote .  Although it 
remains unknown whether ILC2-derived IL-5 and IL-13 contribute to cold 
stress-induced beiging, ILC2-derived enkephalin peptides can act 
directly on beige adipocytes to upregulate UCP1.  This results in 
increased energy expenditure and decreased adiposity that may 
counteract weight gain.  In the setting of obesity, IL-33 expression in 
WAT is increased, however WAT ILC2s are paradoxically decreased in 
both mice and humans, suggesting that the IL-33/ILC2 axis is 
dysregulated in obesity.  This may impede the ability of ILC2s to 
contribute to the function of beige fat, resulting in a vicious cycle that 
promotes weight gain. 
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